<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C0A8CBED-B811-465F-AF71-1DE3F54CA2EA"><gtr:id>C0A8CBED-B811-465F-AF71-1DE3F54CA2EA</gtr:id><gtr:name>CARIS Life Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB05C424-91BF-4B48-9472-E6F6226A6A05"><gtr:id>CB05C424-91BF-4B48-9472-E6F6226A6A05</gtr:id><gtr:name>University of London</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Malet Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 7HU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6F706D37-32CA-43E1-B3AF-26129E458937"><gtr:id>6F706D37-32CA-43E1-B3AF-26129E458937</gtr:id><gtr:name>Royal Marsden Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BC527630-1FFE-4CB4-B63C-AD43768307DB"><gtr:id>BC527630-1FFE-4CB4-B63C-AD43768307DB</gtr:id><gtr:name>Biosignatures</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/931F0B0D-E479-4E31-AF94-5CCAFB6A4445"><gtr:id>931F0B0D-E479-4E31-AF94-5CCAFB6A4445</gtr:id><gtr:name>deCODE Genetics</gtr:name><gtr:address><gtr:line1>Sturlugata 8</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/091A7281-194A-4C7B-8E9A-0CEB4FEE954B"><gtr:id>091A7281-194A-4C7B-8E9A-0CEB4FEE954B</gtr:id><gtr:name>Faculty of Medicine</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C0A8CBED-B811-465F-AF71-1DE3F54CA2EA"><gtr:id>C0A8CBED-B811-465F-AF71-1DE3F54CA2EA</gtr:id><gtr:name>CARIS Life Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A8F2AA65-FB13-45D8-96BA-E478CE387554"><gtr:id>A8F2AA65-FB13-45D8-96BA-E478CE387554</gtr:id><gtr:name>Karolinska University Hospital</gtr:name><gtr:address><gtr:line1>Karolinska University Hospital</gtr:line1><gtr:line2>Huddinge</gtr:line2><gtr:postCode>SE 141 86</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB05C424-91BF-4B48-9472-E6F6226A6A05"><gtr:id>CB05C424-91BF-4B48-9472-E6F6226A6A05</gtr:id><gtr:name>University of London</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Malet Street</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 7HU</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6F706D37-32CA-43E1-B3AF-26129E458937"><gtr:id>6F706D37-32CA-43E1-B3AF-26129E458937</gtr:id><gtr:name>Royal Marsden Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7"><gtr:id>4EBF3DC3-B4A4-4E4E-B13D-284698AA70D7</gtr:id><gtr:name>Dana-Farber Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BC527630-1FFE-4CB4-B63C-AD43768307DB"><gtr:id>BC527630-1FFE-4CB4-B63C-AD43768307DB</gtr:id><gtr:name>Biosignatures</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/931F0B0D-E479-4E31-AF94-5CCAFB6A4445"><gtr:id>931F0B0D-E479-4E31-AF94-5CCAFB6A4445</gtr:id><gtr:name>deCODE Genetics</gtr:name><gtr:address><gtr:line1>Sturlugata 8</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/091A7281-194A-4C7B-8E9A-0CEB4FEE954B"><gtr:id>091A7281-194A-4C7B-8E9A-0CEB4FEE954B</gtr:id><gtr:name>Faculty of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E21F9419-E970-4374-AAA6-C0C97401C46E"><gtr:id>E21F9419-E970-4374-AAA6-C0C97401C46E</gtr:id><gtr:firstName>Jenny</gtr:firstName><gtr:surname>Donovan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/919C856C-451C-40F1-A5E3-90742AEA6997"><gtr:id>919C856C-451C-40F1-A5E3-90742AEA6997</gtr:id><gtr:firstName>F</gtr:firstName><gtr:surname>Hamdy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/63E0AEE1-6D8D-4425-A06A-F4A943FFAF21"><gtr:id>63E0AEE1-6D8D-4425-A06A-F4A943FFAF21</gtr:id><gtr:firstName>David Edgar</gtr:firstName><gtr:surname>Neal</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900871"><gtr:id>47B42D12-2855-448B-AA7A-A8FB0CA30A80</gtr:id><gtr:title>ProMPT Renewal</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900871</gtr:grantReference><gtr:abstractText>Prostate cancer is the commonest solid tumour in men. We deperately need biomarkers that predict how in the future an individual cancer is likely to behave. The development of a clinically linked repository across the two prostate cancer collaboratives is critical in achieving this, and will underpin the science that is funded through more conventional routes.</gtr:abstractText><gtr:technicalSummary>The two prostate cancer collaboratives are moving towards the provision of infrastructure only for the remaining two years of the funding. We are concentrating on developing a clinically linked bio-bank for prostate cancer for tissue, nucleic acids, and paraffin embedded tissue, as well as liquid based collections.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>331813</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Medicine</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Medical Biophysics</gtr:department><gtr:description>York - Toronto : Radiation sensitivity of prostate cancer stem cells</gtr:description><gtr:id>A981CFC4-3530-4CE7-8922-5B673EB1D013</gtr:id><gtr:impact>not known</gtr:impact><gtr:piContribution>Radiation sensitivity of prostate cancer stem cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Memorial Sloan Kettering Cancer Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Oxford - MSKCC New York</gtr:description><gtr:id>78675760-A5A2-4FE8-840D-EB3507233DE0</gtr:id><gtr:impact>Vickers et al Clin Cancer Res 2010</gtr:impact><gtr:partnerContribution>Collaboration on prostate cancer prediction using PSA</gtr:partnerContribution><gtr:piContribution>Provision of data from Protect / ProMPT</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Research UK (ICR)</gtr:department><gtr:description>Oxford - Data Unification</gtr:description><gtr:id>DAF60C33-E638-46AD-A296-0EEE8209F731</gtr:id><gtr:impact>New website opened in November</gtr:impact><gtr:partnerContribution>Data Unfiication between ICR, Cambridge and Oxford</gtr:partnerContribution><gtr:piContribution>Data Unification for prostate cancer database on ProMPT/ProtecT patients between Northern and Southern Collaboratives</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Research UK (ICR)</gtr:department><gtr:description>Cambridge / ICR / Marsden - Next Generation Sequencing</gtr:description><gtr:id>4C853DC0-44FE-45F3-AF96-C791E2956FEB</gtr:id><gtr:impact>na</gtr:impact><gtr:partnerContribution>joint exchange of know howjoint exchange of know how</gtr:partnerContribution><gtr:piContribution>Next generation sequencing. This is a proof of principle study which if goes ahead will result in &amp;pound;16.5 million extra funding.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Research UK (ICR)</gtr:department><gtr:description>Cambridge - Colin Cooper - Whole Genome Sequencing</gtr:description><gtr:id>A6F96FBF-01CD-4FCF-9FAF-4AC974E86C2A</gtr:id><gtr:impact>Grant application due to be announced 1st week in December</gtr:impact><gtr:partnerContribution>Collaboration with Colin Cooper to put in a request to CRUK for funding for whole genome sequencing for prostate cancer. This is likely to lead to a very major award and a major impact on prastate cancer practice.</gtr:partnerContribution><gtr:piContribution>Development of idea; careful development of methodologies for tissue processing; will be contributing a major number of cases</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Surgical Sciences Oxford</gtr:department><gtr:description>Oxford / Cambridge / Bristol</gtr:description><gtr:id>8B426F6D-37C9-4474-ABCC-D9309425EEC9</gtr:id><gtr:impact>Submission of an outline application to carry out studies of novel diagnositc pathways including the role of SNPs and gentyping to NIHR</gtr:impact><gtr:partnerContribution>Submission of an outline application to carry out studies of novel diagnositc pathways including the role of SNPs and gentyping to NIHR</gtr:partnerContribution><gtr:piContribution>joint exchange of know how</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biochemistry Bristol</gtr:department><gtr:description>Bristol - Role of Fascin in prostate cancer prevention</gtr:description><gtr:id>CC7468AA-0A59-4B18-B299-9067E4502EF7</gtr:id><gtr:impact>Ongoing work towards PhD</gtr:impact><gtr:partnerContribution>Professor Richard Martin has developed a collaboration with Professor Jo Adams (Dept of Biochemistry, University of Bristol) to investigate the role of fascin in prostate cancer prevention. They are co-supervising a Wellcome Trust funded PhD student to undertake the work.</gtr:partnerContribution><gtr:piContribution>Co-supervision of PhD Student</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Oxford/Cambridge - collaboration with Henrik Gronberg Karolinska Institute</gtr:description><gtr:id>989D0CD6-5095-4B92-80D6-9435DEF57E6D</gtr:id><gtr:impact>New meeting in Oxford in 2011 to take this project forward</gtr:impact><gtr:partnerContribution>Joint exchange of know how</gtr:partnerContribution><gtr:piContribution>TMAs received from Karolinska for novel biomarker studies
Tissue being sent to Karolinska for expression studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Marsden Hospital NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cambridge / ICR / Marsden - Next Generation Sequencing</gtr:description><gtr:id>F1661857-79A5-420E-A403-25EFB7C52079</gtr:id><gtr:impact>na</gtr:impact><gtr:partnerContribution>joint exchange of know howjoint exchange of know how</gtr:partnerContribution><gtr:piContribution>Next generation sequencing. This is a proof of principle study which if goes ahead will result in &amp;pound;16.5 million extra funding.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska University Hospital</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Oxford/Cambridge/Stockholm</gtr:description><gtr:id>B3A8A568-25BD-4FFF-BEA6-FD59B3580E51</gtr:id><gtr:impact>New meeting in Cambridge in 2012</gtr:impact><gtr:partnerContribution>To look at SNP profiling and new diagnostic pathways in prostate cancer. Possible application to European Union funding. Joint exchange of know how</gtr:partnerContribution><gtr:piContribution>To look at SNP profiling and new diagnostic pathways in prostate cancer.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>deCODE genetics</gtr:collaboratingOrganisation><gtr:country>Iceland, Republic of</gtr:country><gtr:description>Cambridge - EC Funding</gtr:description><gtr:id>6DE4AC59-0E3A-4A89-B57C-8DE1BB46E046</gtr:id><gtr:impact>Grant awarded from EC</gtr:impact><gtr:partnerContribution>collaboration with other EC departments</gtr:partnerContribution><gtr:piContribution>Running clinical studies group</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial College of Science Technology and Medicine (ICSTM)</gtr:department><gtr:description>Newcastle - ICL</gtr:description><gtr:id>608184DF-5664-48DF-89C4-D4B4CE4CBA28</gtr:id><gtr:impact>not known</gtr:impact><gtr:piContribution>Collaboration with the Bevan Group at ICL - included use of prostae cancer tissue microarray and led to publication of research in Cancer Research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biosignatures</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Newcastle - Biosignatures</gtr:description><gtr:id>F0406D53-19FF-49D7-B1EE-D7D60A0B125E</gtr:id><gtr:impact>not known</gtr:impact><gtr:piContribution>A company with specialist bioinformatics expertise. Defining a protein signature for prostate cancer patients using blood samples and 2D gel electrophoresis. Possible access to stored blood samples from ProtecT/ProMPT.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CARIS Life Sciences</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Oxford - CARIS epigenetics project</gtr:description><gtr:id>00AD3294-F72A-454F-8A72-FCC611217C1F</gtr:id><gtr:impact>New funded project</gtr:impact><gtr:partnerContribution>Epigenetics project in prostate cancer</gtr:partnerContribution><gtr:piContribution>Novel project studying methylation in prostate cancer. We are providing a well-annotated bio-repository.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Cambridge - GSK Novel metabolic inhibitors</gtr:description><gtr:id>67D75970-225C-440C-97D9-007160A7A23C</gtr:id><gtr:impact>To look at novel metabolic inhibitors involved in prostate cancer. Currently pre-clinical and involving novel imaging technologies (C11 acetate but likely to move to man in the near future).</gtr:impact><gtr:partnerContribution>joint exchange of know how to look at novel metabolic inhibitors involved in prostate cancer. Currently pre-clinical and involving novel imaging technologies. (C11 acetate but likely to move to man in the near future)</gtr:partnerContribution><gtr:piContribution>joint exchange of know how</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Newcastle - AstraZeneca</gtr:description><gtr:id>FC7CA0B4-AA56-466A-BC9A-1BA4AE0E8233</gtr:id><gtr:impact>not known</gtr:impact><gtr:piContribution>Developing further collaboration iwht AstraZeneca using novel androgen receptor antagonists they have developed.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Dana-Farber Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Medical Oncology</gtr:department><gtr:description>Cambridge - NCI - functional effects of SNPs</gtr:description><gtr:id>1A54FA35-687C-420D-B9E5-748C58A9284B</gtr:id><gtr:impact>Awarded grant from NCI</gtr:impact><gtr:partnerContribution>verification of expression data in prostate cancer</gtr:partnerContribution><gtr:piContribution>Collaboration on laboratory work with Dana Faber</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Research UK (ICR)</gtr:department><gtr:description>Cambridge - ICOGS, PRACTICAL, NIH Consortium</gtr:description><gtr:id>24312C01-E282-4D01-87A5-C046C5A85C1C</gtr:id><gtr:impact>See publications (x2 Nature Genetics; x1 JNCI plus others)</gtr:impact><gtr:partnerContribution>Request to join in collaborations within Europe, Australia and the US for prostate cancer whole genome sequencing. We are now formally a part of a number of collaborations which are funded including ICOGS, PRACTICAL and a NIH consortium</gtr:partnerContribution><gtr:piContribution>DNA from our collections formed a significant number of the cases and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Research UK (ICR)</gtr:department><gtr:description>Glasgow - ERK5</gtr:description><gtr:id>57ABFCDD-3146-4031-BF42-36A89155AE0B</gtr:id><gtr:impact>not known</gtr:impact><gtr:piContribution>Collaboration with TAPG on ERK5 expression analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>York - Masonic Lodge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C88511ED-2964-48E2-91F0-1D9C2DCE3B9D</gtr:id><gtr:impact>Dr Davide Pellacani attended a dinner of the local Masonic Lodge who have sponsored some of his research as part of a grant to YCR.

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - BBC Local Radio</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F6A2027F-EEDA-4865-B8BE-2D80BDD336BE</gtr:id><gtr:impact>Review of the newspapers on the local BBC Radio station giving a scientific point of view and selecting articles of scientific interest to the general public

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Laboratory open evenings</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>6EAFF37A-A454-4D1A-B09E-B726E7027314</gtr:id><gtr:impact>My group have presented public information lectures at laboratory open evenings. On each evening, 3 graduate students gave short accounts of their thesis research followed by question and answer sessions and a guided tour of the Department with demonstrations of some key (and stimulating) technology.

na</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Local patient support groups and schools</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FAF81BEA-8FA7-4247-A2CB-B2627D6E9749</gtr:id><gtr:impact>Regular non-scientific account of research to local patient support groups and local schools

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Presentation to Masonic Grand Charity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>EAD843AF-9BE1-4B35-92A0-365006FCA930</gtr:id><gtr:impact>Presented talks at Masonic functions and assisted in preparing an information sheet for Masons on benefits of being screened for prostate cancer

Three non-symptomatic tumours from 1000 patients have been detected.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle - CRUK Fundraising Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D7729B95-D225-4828-9218-E486FBCB63F1</gtr:id><gtr:impact>Two large organised CRUK Fundraising events that mentioned MRC funded research

additional grant funding for the group</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle - Northern Institute for Cancer Research Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FCB9013F-E3AA-41B0-BC29-35839965C732</gtr:id><gtr:impact>Presentations to local fundraisers

not known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridgeshire Prostate Cancer Support Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3C63E149-844A-41B1-8E2E-CFED0E676823</gtr:id><gtr:impact>200 patients and family members attended a talk on the translational research programmes

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle - Presentation Rotterdam, Amsterdam, ICR, Washington</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>CA3C54AA-823F-4FF8-B93E-A0773A065B5B</gtr:id><gtr:impact>Presentations at conferences in Rotterdam, Amsterdam, ICR and Washington

Not known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge - lay audiences and media</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>FBAF50C3-26DC-4C19-8165-8152D1D2E651</gtr:id><gtr:impact>various lay audiences locally and nationally

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Local patient support group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>CD5EF95B-4E74-4035-BAE0-061FDF096143</gtr:id><gtr:impact>Presentation of output of our research to a local patient support group at York Hospital, to two local YCR fund raising committees and to the annual meeting of all YCR collection committees.

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle - Race for Life</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>6846D740-9265-415E-8621-E01BB8D32E28</gtr:id><gtr:impact>short talks and discussions at Regional Cancer Charity fund raising events - Race for Life (Newcastle and Gateshead)

na</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Prostate Cancer Charity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4C9E3E58-4061-44A4-A41D-03B279F66A89</gtr:id><gtr:impact>A formal lecture on new screening methods for prostate cancer to the Prostate Cancer Charity Patients' Forum held at the Central Hall Westminster

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - SKY News and Radio 4</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F4066968-F871-4F00-80E4-3A73C81982C0</gtr:id><gtr:impact>Appearance on SKY News and contribution to the Radio 4 programme Saving the Earth, discussing the use of jellyfish proteins for cancer imaging.

NA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge - CRUK Cambridge Research Institute</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>AEDD9FF4-D993-4F8A-BE66-9A5527FA3DCE</gtr:id><gtr:impact>Dr Hayley Whitaker regularly presents to non-academic audiences who are interested in the translational research being carried out at the Institute.

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Senior Investigator Award</gtr:department><gtr:description>Cambridge - NIHR Senior Investigator Award</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>1077D83A-9B76-406A-8A49-3094D230A1F4</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>248975</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford - Prostate Cancer Charity</gtr:description><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>35E73171-C6D5-41FC-927E-280FD5AF3B18</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Bristol - NIHR</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>EA66C079-C123-4B1C-B6D7-DF1356B055DB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle - CRUK</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>15EA5ECB-8261-419B-B341-05AB5503793B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle CRUK/AstraZeneca/CRUK/AstraZeneca jointly</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Autistica</gtr:fundingOrg><gtr:id>AD58884E-218E-44F7-97F4-49829C9E76C1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44840</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Above and Beyond Grants</gtr:department><gtr:description>Bristol charity - Above &amp;amp; Beyond</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>University Hospitals Bristol NHS Foundation Trust</gtr:fundingOrg><gtr:id>CCEED1D2-F1B8-447F-86A3-2EE7DB527431</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>526925</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford - Pro-nest</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>C6B37015-2B8A-47FA-AD91-B715AF6BDE91</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>York - Yorkshire Cancer Research</gtr:description><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>FFF52D01-5371-42E8-AE70-BF427C0C2C8C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Cambridge/Bristol/Oxford - NIHR, HTA, ProtecT</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>51D2265D-0CF3-40D4-A418-028B13ED3D62</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>York - Yorkshire Cancer Research</gtr:description><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>D12D5348-35FD-499C-93AA-41D88DEEF3E2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - ICGC - next generation sequencing</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>3B431EA2-120D-4049-9DC2-0B2034EC740A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>319815</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Bristol - NIHR</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>23F5843B-9B55-4B4C-B752-670B53205968</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>525098</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - CRUK TRICC</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>ADC264ED-C496-47FB-BFD8-730E2CBBF3A8</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>189534</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bristol - CRUK</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>2B9912AB-5431-4125-810E-0BA1353A5AC9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Senior Investigator Award</gtr:department><gtr:description>Oxford - NIHR Senior Investigator award</gtr:description><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>0C4B979D-9558-4F9B-A17B-3A6D5EF7E07F</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188564</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - CANCURE (2m euros across 11 participants)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>91C6D9E2-8375-42E6-8CB4-460D9B3C81E0</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>176237</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge Cancer Research Fund</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>0A0E9BC3-B188-446E-B38F-CCDFE96840B3</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48425</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - National Institute of Health</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>923AFCE4-6D83-4E8E-BB5B-2062B92D8359</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge/Bristol/Oxford - CAP</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>48CADEBF-D38B-496A-AB64-C3BAC6871BF4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1439674</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - CRUK Programme Grant</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>7C707E32-08DE-4271-816B-976D7DCCD916</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>34803</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bristol - BMA Gunton Award</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>B67793AF-EA35-4AD3-B5C2-9998C9BDD540</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>175000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Sanofi-Aventis</gtr:department><gtr:description>Newcastle - Sanofi Aventis</gtr:description><gtr:fundingOrg>Sanofi</gtr:fundingOrg><gtr:id>21F0A117-82B3-4F1F-AE1F-EDE6F600B72F</gtr:id><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100747</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - Cytosystems</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>Cytosystems Ltd</gtr:fundingOrg><gtr:id>D5CE01C0-3372-4A81-A68D-9521768C27AB</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>207000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Philips</gtr:department><gtr:description>Cambridge - PHILIPS</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Koninklijke Philips Electronics N.V.</gtr:fundingOrg><gtr:id>2A14A8C4-918D-4033-8E5A-CE7E38D57EC7</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>341510</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - ProMark</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:id>7B3F6824-4E88-40E9-88E9-AFE1A8C538C9</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle - Prostate Cancer Charity</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>49FCCD4C-DC01-4B4D-9EDE-17A6EC6D94F1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>224387</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bristol - WCRF</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>World Cancer Research Fund (WCRF)</gtr:fundingOrg><gtr:id>2DC7892B-375B-4188-951F-95BEEC55EE37</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Discloses antagonists of PTT521, specifically nucleic-acid based (e.g. siRNA), which induces cancer stem/progenitor cells to differentiate and stop dividing. The claims are also directed to liposome delivery of siRNA.</gtr:description><gtr:id>C366EDB4-B8E8-4F97-A8DF-7B9BDB362B1E</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP1689</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Two new novel biomarkers which will be prognostic are being taken through by Cancer Research Technologies to IP protection</gtr:description><gtr:id>637F562D-2A35-42EF-8618-672718C7CDE5</gtr:id><gtr:impact>na</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Cambridge - two novel biomarkers</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The patent discloses a genetically engineered baculovirus biotherapy vector that is modified to target the baculovirus to a cell that expresses either gonadotropin receptor or neurotensin receptor (i.e. the prostate).</gtr:description><gtr:id>9308B45E-D0BA-4E1F-A0B4-11A186DEEE63</gtr:id><gtr:impact>Facilitation of collaborative reserach with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP 0072</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Total of more than 30 worldwide applications in prostate biology and cancer stem cells currently being progressed (mostly transferred to University Spin out company Pro-Cure Therapeutics). Key patents on Prostate 3D modelling have granted in USA, Europe and UK, and Cancer stem cell isolation has granted in UK, Europe awaiting grant in USA, Japan, Australia, Canada.</gtr:description><gtr:id>8674C9E5-F55D-4208-84B9-17884235EAAE</gtr:id><gtr:impact>see above</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - various applications</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This application covers non-human mammalian models, and processes to produce them, for the analysis of cancer stem cells and the use of the models in the identification and validation of agents useful in the treatment of cancer.</gtr:description><gtr:id>DDC31558-2EE2-4147-88DA-B65513EA91C3</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP4039</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The application discloses the full array data generated from CD133+ prostate cancer stem cells. Claims have been limited to PTT273 as a prostate CSC marker; siRNAs derived from PTT273; vaccines comprising PTT273 and methods to screen for agents that inhibit PTT273. 
Divisional application strategy in play, to sequentially protect subsequent targets, agents against them and diagnostics for them.</gtr:description><gtr:id>C94DCFCF-239D-4FB5-A98D-C21DB3EAF736</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP0068</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Claims agents that inhibit the expression or activity of PTT522, including methods to treat cancer using the agents.</gtr:description><gtr:id>CD1E9189-5F86-4ABB-BEB5-4CABB5BD0EA9</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP3787</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The application relates to a modified baculovirus that targets PTT521 inhibitory RNA (e.g. siRNA, antisense RNA, micro RNA) to prostate cancer cells.</gtr:description><gtr:id>B2DFE63C-445C-4EDB-A323-FB0BEF4311AF</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP3497</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>New PCT filing (PCT/GB2011/051913) relating to a group of genes that could serve as markers of prostate cancer and possible targets for therapeutic intervention.</gtr:description><gtr:id>F2D4BE6C-C158-41CD-A6D0-46B077AC287E</gtr:id><gtr:impact>see above</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2012046064</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>York - PCT filing</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Recent publication in PLoS One made the front page of the Daily Mail and Daily Telegraph. IP discussions are taking place with a company to discuss the MSMB assay.</gtr:description><gtr:id>4F8642FD-6650-4517-B500-92C1AF9FA7B4</gtr:id><gtr:impact>Paper in PLOSOne</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Cambridge - MSMB assay</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The patent discloses the isolation and characterization of an enriched population of CD133+ cancer stem cells; pure cell cultures of prostate CSCs; animal models containing them; cell based vaccine compositions amongst other claims.</gtr:description><gtr:id>790AB8EC-719C-4CC9-8F21-DF608CDDF770</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP0069</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The applications disclose vaccine compositions comprising PTT273 and fragments derived from PTT273 and their use in the treatment of cancer, specifically prostate cancer.</gtr:description><gtr:id>1D2ECF24-C145-4CDF-8028-011DA11ECFE8</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>US20120100102</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>York - HIP1709</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The patent discloses a method for the growth and maintenance of cancerous prostate acini and their use in drug screening</gtr:description><gtr:id>2ED547B6-7993-4A7C-8FDC-A3DB1DF2EF86</gtr:id><gtr:impact>Facilitation of collaborative research with other groups.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>York - HIP0073</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glasgow - National Prostate Cancer Quality Performance Indicator Development Group Scotland</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>52685AAD-97C7-44FE-B826-8773ECC14F97</gtr:id><gtr:impact>Influence and input to this committee</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - Deutsch Kerbshilfe</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>5BF1F1B8-3B32-4030-8404-D00D99F6EE71</gtr:id><gtr:impact>Invited to strategy discussions/meetings Deutsch Kerbshilfe, Germany (National Cancer Charity)</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - Biomedical Research Centre/Oxford Radcliffe Bio-Repository</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>93881608-46BE-44CE-9479-7923ACB26806</gtr:id><gtr:impact>Invited to join steering committee of Oxford Biomedical Research Centre and Oxford Radcliffe Biorepository</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cambridge - National Prostate Audit</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>0ACA5B50-EF86-407A-9640-67AAF79B753E</gtr:id><gtr:impact>Prof Neal has led a consortium to obtain funding for a prostate cancer audit supported by a number of stakeholders including BAUS, BAUN, BUG and others. This will be substantial funding over the next quinquennium and will directly improve prostate cancer care.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Newcastle - Member of NCRI Biomarkers and Imaging Group</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>64AC334B-633F-4921-B6D0-557BF652D50B</gtr:id><gtr:impact>Influence and input to this committee</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - Gothenburg University</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>6092FC0B-634F-4569-913E-8FF8E4DB3B35</gtr:id><gtr:impact>RAE equivalent and external review</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>York - Scientific Chair of the Orchid Trust (LONDON)</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>F49AD990-2A6D-409F-A1C3-33A3B946E9A5</gtr:id><gtr:impact>not known</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Newcastle - Prostate Cancer Charity SAC</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>406678D1-7ABC-4535-822C-E86DC20F7FDC</gtr:id><gtr:impact>Influence and input to this committee</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Newcastle - NCRI Prostate Clinical Studies Group</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>07A4556A-F072-4141-A0B1-2AC42719A82F</gtr:id><gtr:impact>Influence and input to this committee</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>York - Association of Medical Research Charities</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>48A305B3-1446-4152-B1C2-EC955FDF9B4C</gtr:id><gtr:impact>Presented to and shared in the evolution of a policy document from the Association of Medical Research Charities on academic spin out companies and intellectual property.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bristol - Member of National Awareness and Early Diagnosis Initiative</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>C19E36FF-361D-417C-B6A7-A115FCC70018</gtr:id><gtr:impact>Input and influence to this national committee</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cambridge - Prostate Cancer Advisory Group - Screening Policy Group</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>B7CA66E6-59DA-4F69-B761-BCA278107768</gtr:id><gtr:impact>Recent editorials from Professor Neal are now being considered by the Screening Policy Group at the Dept of Health.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - NCI USA</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C0693AEC-D17C-4CD7-9F67-FB967987F3B9</gtr:id><gtr:impact>Invited to advice on biobanking policies</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>York - Chair - French Prostate Cancer Committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>4307EADA-757C-450D-B14B-E8F2AE69F1E2</gtr:id><gtr:impact>not known</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bristol - Epidemiology Course</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>898241EF-B002-46B1-A78E-DB0EB400C539</gtr:id><gtr:impact>Cancer Epidemiology 3 day short course</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Glasgow - Trustee for Prostate Cancer Charity</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>5F69E0C4-8AAB-4AD5-98D2-90D27D609CFB</gtr:id><gtr:impact>Influence to this Charity</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bristol - CRUK Population Research Committee Member</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>F3739A7D-7231-4BC7-B79B-B51E5C9C186D</gtr:id><gtr:impact>Influence on policy and funding by the CRUK Population Research Committee</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - Member of HTA Commissioning Board</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>D277BED6-4945-431A-B4C0-9BAA79A48FC0</gtr:id><gtr:impact>Member of HTA Commissioning Board</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - French Ministry</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>D3085FFF-5D60-472A-9010-A3D9C0CE2EB1</gtr:id><gtr:impact>External speaker/advisor, French Ministry, Convention on Health Analysis and Management</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>York - Kuwaiti and Qatari National Research Programme Advisor</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>0DBC8636-1839-4F09-BE48-ABBD69F65A01</gtr:id><gtr:impact>not known</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>siRNA against cancer stem cells</gtr:description><gtr:id>36B07474-6B91-4F93-BBEB-61DD5F5EBC33</gtr:id><gtr:impact>ongoing develoment</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>York - series of siRNA reagents</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Initial results were promisiing, but later problem were identified</gtr:description><gtr:id>021F1F6D-2636-4E52-9BC5-3C9ADBBD5730</gtr:id><gtr:impact>Some funding initially by spin-out company</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>York - monoclonal antibodies target gene PTT273</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have demonstrated the effectiveness of inhibition of a number of potential cancer stem cell targets by SiRNA inhibition in animal models. Again a number of patents to cover this have been filed (by Pro-Cure Therapeutics)</gtr:description><gtr:id>3C1B2E34-6135-443B-91FE-4B4439BB265C</gtr:id><gtr:impact>We have demonstrated the effectiveness of inhibition of a number of potential cancer stem cell targets by SiRNA inhibition in animal models. Again a number of patents to cover this have been filed (by Pro-Cure Therapeutics)</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>York - SiRNA inhibition</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Measurement of MSMB to diagnose prostate cancer</gtr:description><gtr:id>6AD17F1B-7428-49DD-95A5-8D9564DAD56E</gtr:id><gtr:impact>Paper in PLOS one; continued validation and interaction with several companies</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>ELISA for MSMB</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have co-developed a vaccine (still at animal experimental stage) against prostate cancer stem cells with the University of Sheffield. IP has been filed jointly.</gtr:description><gtr:id>CD5A9E21-D378-40A8-9524-D9852DB6A95A</gtr:id><gtr:impact>We have co-developed a vaccine (still at animal experimental stage) against prostate cancer stem cells with the University of Sheffield. IP has been filed jointly.</gtr:impact><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>York - vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Generation of &amp;gt;100 monoclonal antibodies against a prostate cancer stem cell target PTT273. Of these, 3 were selected with the highest PTT273 enzyme inhibiting activity which were able to co-select with the AC133 antibody for CSC's in primary tissue. However, affinity was insufficient to use for in vivo inhibition experiments (this was largely funded and carried out in Pro-Cure Therapeutics as part of our therapeutic development programme)</gtr:description><gtr:id>2BEF79C8-FDED-4783-AA54-C05C62E38CAD</gtr:id><gtr:impact>Start up funding for new biotech company</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - PTT273</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>1500 cases and controls nested within ProtecT Study</gtr:description><gtr:id>EEAE7BE7-3907-436F-AE66-B45029C91F17</gtr:id><gtr:impact>Contribution to papers on GWAS (x2 Nature Genetics; xa JNCI)</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bristol - GWAS controls</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Ethics approval that has made anew line of enquiry possible.</gtr:description><gtr:id>0BDEE696-E508-49A8-8680-2DC239E89633</gtr:id><gtr:impact>New ethics approval for collection of bone marrow/bone biopsies prospectively from prostate cancer patients to study bone microenvironment.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Oxford - New Ethics Approval for bone marrow/bone biopsy</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>new research section</gtr:description><gtr:id>C7BB68F4-7338-46AF-B088-DBECB6517023</gtr:id><gtr:impact>Establishment of Surgical Oncology as new section of the CRUK Oxford Cancer Research Centre</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Oxford - new Surgical Oncology section</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>artificial intelligence (fuzzy logic)</gtr:description><gtr:id>8BABDABD-A32E-476C-9125-05E8335ACCD5</gtr:id><gtr:impact>Continuing development of artificial intelligence (fuzzy logic) to interpret clinicopathological data to predict disease outcome, and large array data analysis.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Oxford - artificial intelligence</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The previously funded CANCAP project jointly between Cooper and Neal is now being analysed and will include CGH array technology and SNP6 results which again when published will be available as a public resource.</gtr:description><gtr:id>8013BBC9-C319-47F7-9FF8-A4BB76821FAB</gtr:id><gtr:impact>The previously funded CANCAP project jointly between Cooper and Neal is now being analysed and will include CGH array technology and SNP6 results which again when published will be available as a public resource.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cambridge - CANCAP</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Joint database for prostate cancer collections funded under ProMPT is being set up together with the Sountern Collaborative. The database will go live to offer researchers the opportunity to send in bids to access specimens in the excess specimens collected as part of ProMPT</gtr:description><gtr:id>35066E5C-9917-4F87-8313-01F23D88EF8E</gtr:id><gtr:impact>New web-based access for tissue just activated</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cambridge - Prostate Cancer collections - collaboration with Southern Collaborative</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed a new and relevant in vivo xenograft model for prostate cancer in immunocompromised mice (Rag2-/-, GammaC -/-). We are able to serially transplant and to freeze tumour cell aliquots from an original tissue fragment, expanding both the tumour initiating cell population, and providing a testing tool (IP filed by Pro-Cure Therapeutics ) for novel therapeutics. In this model true Gleason grade 6 cancer are NOT tumorigenic, mirroring clinical outcome in human patients, where a Gleason grade 7 (or the presence of a pattern 4 is synonymous with bad prognosis). We now have 15 near patient serially transplantable tumours from both hormone sensitive and castration resistant tumours.</gtr:description><gtr:id>89B46F93-C92E-4F80-9B78-F88657E04012</gtr:id><gtr:impact>We now have 15 near patient serially transplantable tumours from both hormone sensitive and castration resistant tumours.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - Xenograft</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>As part of a collaboration with the York System for Complex System Analysis (YCSSA) we have developed new bioinformatics tools to analyse gene expression datasets, as applied to prostate differentiation. This was funded by a pump-priming grant from YCR. Some of the primary data analysed was generated during and supported in part by the Prompt project.</gtr:description><gtr:id>FB2419A3-348B-4DA6-A243-D1AAF579A0B2</gtr:id><gtr:impact>Funding from YCR</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - YCSSA bioinformatics tool</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed new software tools for (i) in silico modelling of prostate epithelial differentiation and cell fate and (ii) Analysis of candidate prostate cancer genes in 'big datasets' , to identify coregulated genes (IP filed here by Univ of York)</gtr:description><gtr:id>8FFA9964-6DCF-4825-B7B7-BB857B281970</gtr:id><gtr:impact>not known</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - software tools</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Further expansion of prostate cancer tissue microarray</gtr:description><gtr:id>6D14ACDE-D3D9-4C72-BEA9-4328DA5308F5</gtr:id><gtr:impact>not known</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Newcastle - tissue microarray</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Several resources put on line from high throughput sequencing for ChIP sequencing (EMBOJ paper Massie et al). High throughput sequencing available for local ProMPT members including data from paraffin embedded material and initial date from next generation sequencing.</gtr:description><gtr:id>2B56BCF7-7D66-424B-A32B-A98231914B29</gtr:id><gtr:impact>Several resources put on line from high throughput sequencing for ChIP sequencing (EMBOJ paper Massie et al). High throughput sequencing available for local ProMPT members including data from paraffin embedded material and initial date from next generation sequencing.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cambridge - high throughput sequencing</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>1. A series of primary xenografts from patients with Gleason grade 7+ tumours and castration resistant recurrences, with back up of lymphocyte and primary cell cultures from the same patients.
2. A truly malignant xenograft model of prostate cancer primary tissues.
3. The ability to freeze and regraft fractionated human epithelial cells from xenografts</gtr:description><gtr:id>EE6114DE-9339-4820-8A25-9A025052AB56</gtr:id><gtr:impact>Studies underway to carry out expression profiling</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - Xenografts</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated (in collaboration with Univ of Tampere) a microRNA expression database from fractionated cell populations from Normal, malignant and castration-resistant prostate cancer.</gtr:description><gtr:id>20C06D34-9070-4AFF-A1C4-2ABB65D0AAB1</gtr:id><gtr:impact>We have generated (in collaboration with Univ of Tampere) a microRNA expression database from fractionated cell populations from Normal, malignant and castration-resistant prostate cancer.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - microRNA</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Medium scale siRNA library screens and assay development for HTS Specific Phospho-p68 antibody generated</gtr:description><gtr:id>1983436C-FF47-4DBD-B5C9-A0A0DCEB5C78</gtr:id><gtr:impact>Medium scale siRNA library screens and assay development for HTS Specific Phospho-p68 antibody generated</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Newcastle - siRNA library screens and assay development for p68</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Used among collaborating centres within ProMPT</gtr:description><gtr:id>2C698D46-28D1-40B0-9E38-EC8240933737</gtr:id><gtr:impact>new collaborative projects in train</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Glasgow - Docetaxel resistant prostate cancer cells</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have 3 highly specific, but relatively low affinity monoclonal antibodies against a prostate cancer stem cell antigen PTT273, and have generated recombinant protein from this antigen for ELISA on human sera, and sufficient (4mg) of human cell derived protein from another potential CSC antigen PTT256 for monoclonal antibody production (Pro-Cure Therapeutics).</gtr:description><gtr:id>8CD3EB10-C766-4918-A76B-7D578A56F872</gtr:id><gtr:impact>start up funding for new biotech company</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - PTT273</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Database of the following phenotypes nested within the ProtecT study case-control study: components of the IGF system, n=3000 cases and 3000 controls (IGF-I, IGF-II, IGFBP-2, IGFBP-3); vitamins D, A, E, folate, B12, homocystein, n=1500 cases and 1500 controls.</gtr:description><gtr:id>4C36BF3E-2DBD-4C1A-B378-BF762B8FFD36</gtr:id><gtr:impact>Published output on IGFs</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bristol - Phenotypes nested within ProtecT Study case control study</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Pro-Cure Therapeutics Ltd</gtr:companyName><gtr:description>Pro-Cure therapeutics has spun out of our laboratory. 10 scientists at present. Currently negotiating research agreements with two major pharma companies.</gtr:description><gtr:id>A2A0E2FF-A605-41BD-A3F2-6D5053EAB30E</gtr:id><gtr:impact>Novel company employing people in York

? Pro-Cure Therapeutics, my spin out company has continued trading and employing 12 scientists, through difficult times in 2011. The loss of a multi-million pound contract with a major pharma company through policy changes at the parent company, and after extensive 12 months' due diligence has placed the company in severe financial difficulty, and the shareholders have decided to put it up for sale (August 2011). This process is now well under way.</gtr:impact><gtr:url>http://www.pro-cure.uk.com/</gtr:url><gtr:yearCompanyFormed>2010</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Newcastle - NEPAF</gtr:companyName><gtr:description>Collaboration with local proteomics company to investigate protein components of the androgen receptor signalling cascade.</gtr:description><gtr:id>FA183F37-56C8-4D4E-BCB7-6F1010C8A26A</gtr:id><gtr:impact>Already led to one publication (Gaughan et al 2010)</gtr:impact><gtr:yearCompanyFormed>2010</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BECE215E-F8DA-4ECB-963F-D5FF9771CD4A"><gtr:id>BECE215E-F8DA-4ECB-963F-D5FF9771CD4A</gtr:id><gtr:title>Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN.</gtr:title><gtr:parentPublicationTitle>Oncogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2af53529d4c9b9937815c815e76fdfe5"><gtr:id>2af53529d4c9b9937815c815e76fdfe5</gtr:id><gtr:otherNames>Oldridge EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-9024</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41BF4680-611C-4D34-988D-3A211C978AFA"><gtr:id>41BF4680-611C-4D34-988D-3A211C978AFA</gtr:id><gtr:title>Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b33c969b8b2e6a09cc05cd1b67d2679d"><gtr:id>b33c969b8b2e6a09cc05cd1b67d2679d</gtr:id><gtr:otherNames>Morris MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CECA1368-E856-440F-BBD4-92BBD50A38C0"><gtr:id>CECA1368-E856-440F-BBD4-92BBD50A38C0</gtr:id><gtr:title>Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e473c461b478d1e38d8da81a7ff32e3c"><gtr:id>e473c461b478d1e38d8da81a7ff32e3c</gtr:id><gtr:otherNames>Williamson SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DED54591-4E5E-4817-973D-3F1AFCA6C80E"><gtr:id>DED54591-4E5E-4817-973D-3F1AFCA6C80E</gtr:id><gtr:title>Phenotypic modulation of human urinary tract stroma-derived fibroblasts by transforming growth factor beta3.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/957b35b6411b395c9dec34a4ac6b4e71"><gtr:id>957b35b6411b395c9dec34a4ac6b4e71</gtr:id><gtr:otherNames>Heer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CD94656B-1D5B-4744-9275-DF7E7DD3C8EB"><gtr:id>CD94656B-1D5B-4744-9275-DF7E7DD3C8EB</gtr:id><gtr:title>FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ac494d475208dcbe97475e9b9d7b64fd"><gtr:id>ac494d475208dcbe97475e9b9d7b64fd</gtr:id><gtr:otherNames>Brooke GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59FD6E9E-B7FA-4545-B0A4-CD0619E9E3E6"><gtr:id>59FD6E9E-B7FA-4545-B0A4-CD0619E9E3E6</gtr:id><gtr:title>Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/58499905651849a43a3e18bb761c12fb"><gtr:id>58499905651849a43a3e18bb761c12fb</gtr:id><gtr:otherNames>Mathew G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9CB6E6DF-D553-49C3-B092-EA75F494B07B"><gtr:id>9CB6E6DF-D553-49C3-B092-EA75F494B07B</gtr:id><gtr:title>The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f830a256cf28c5d5a9a9781e1d0d8117"><gtr:id>f830a256cf28c5d5a9a9781e1d0d8117</gtr:id><gtr:otherNames>Rowlands MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5F66D8F-EB44-48CF-B9F6-F537B5ADE4CE"><gtr:id>A5F66D8F-EB44-48CF-B9F6-F537B5ADE4CE</gtr:id><gtr:title>AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5744838b41b854700310dabdefc0b2e"><gtr:id>d5744838b41b854700310dabdefc0b2e</gtr:id><gtr:otherNames>Loddick SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87B6E7D0-932F-4FED-A57C-7232B5CBB039"><gtr:id>87B6E7D0-932F-4FED-A57C-7232B5CBB039</gtr:id><gtr:title>Integrating surgery with targeted therapies for renal cell carcinoma: maximizing benefits, minimizing risk.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5695006f0a14fdaa8b40cc87ee828535"><gtr:id>5695006f0a14fdaa8b40cc87ee828535</gtr:id><gtr:otherNames>Clarke NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE108160-B264-430A-93C6-4C0243B65DF9"><gtr:id>EE108160-B264-430A-93C6-4C0243B65DF9</gtr:id><gtr:title>Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51ab7e5d96b0aaae3312a021509a9bd2"><gtr:id>51ab7e5d96b0aaae3312a021509a9bd2</gtr:id><gtr:otherNames>Luxton HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8252F59-B0FF-4AB2-92E5-6B01894A1C4C"><gtr:id>D8252F59-B0FF-4AB2-92E5-6B01894A1C4C</gtr:id><gtr:title>Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a11d8ace5349d51fb09158dba3b4a11a"><gtr:id>a11d8ace5349d51fb09158dba3b4a11a</gtr:id><gtr:otherNames>Down L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A569223-F7D1-40B4-862F-E04A31B4DAB3"><gtr:id>5A569223-F7D1-40B4-862F-E04A31B4DAB3</gtr:id><gtr:title>Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5911ce2f2ce71b2e98bcf7b340bfcce8"><gtr:id>5911ce2f2ce71b2e98bcf7b340bfcce8</gtr:id><gtr:otherNames>Burska UL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A2E997D0-FA1E-49EF-A565-F8497F0D7DD6"><gtr:id>A2E997D0-FA1E-49EF-A565-F8497F0D7DD6</gtr:id><gtr:title>Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/70862736759c7f4aeb94a67cf6dbe7a2"><gtr:id>70862736759c7f4aeb94a67cf6dbe7a2</gtr:id><gtr:otherNames>Gilbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A1C740D0-E75E-4A4D-9469-52F635001F1B"><gtr:id>A1C740D0-E75E-4A4D-9469-52F635001F1B</gtr:id><gtr:title>Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0567f8eebf7db3e5c72de58de70706ff"><gtr:id>0567f8eebf7db3e5c72de58de70706ff</gtr:id><gtr:otherNames>Lee JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DC4205B0-8B78-4148-ADA3-B7ACE07BA3B2"><gtr:id>DC4205B0-8B78-4148-ADA3-B7ACE07BA3B2</gtr:id><gtr:title>?-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ca0f5e385ea7be4f8f9a44484558586"><gtr:id>5ca0f5e385ea7be4f8f9a44484558586</gtr:id><gtr:otherNames>Ahmad I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3FCE70C2-6DC6-493B-8247-A29045576660"><gtr:id>3FCE70C2-6DC6-493B-8247-A29045576660</gtr:id><gtr:title>A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d9f33140df805d286b294086ecac8e"><gtr:id>40d9f33140df805d286b294086ecac8e</gtr:id><gtr:otherNames>Pooley KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57D51710-C9B3-467C-8292-3878EBE0D05C"><gtr:id>57D51710-C9B3-467C-8292-3878EBE0D05C</gtr:id><gtr:title>Genome-wide association study identifies new prostate cancer susceptibility loci.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0fd7a99ad803d87bb45f67651daa6a8f"><gtr:id>0fd7a99ad803d87bb45f67651daa6a8f</gtr:id><gtr:otherNames>Schumacher FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58BFCA15-78F6-461B-8B93-8F0CBEBE2BCA"><gtr:id>58BFCA15-78F6-461B-8B93-8F0CBEBE2BCA</gtr:id><gtr:title>The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf74c4ce52e3ecae0d8fce482d5ca56f"><gtr:id>cf74c4ce52e3ecae0d8fce482d5ca56f</gtr:id><gtr:otherNames>Kang D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5EDE91B-AD0F-41DC-AEB4-193F960A5C42"><gtr:id>A5EDE91B-AD0F-41DC-AEB4-193F960A5C42</gtr:id><gtr:title>A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9dc907cd5e9284df572879baedd5e328"><gtr:id>9dc907cd5e9284df572879baedd5e328</gtr:id><gtr:otherNames>Moad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A616248-BEAE-4B96-8464-EC450E9861B8"><gtr:id>4A616248-BEAE-4B96-8464-EC450E9861B8</gtr:id><gtr:title>Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e29080962d481ae8af4509c5a8c39045"><gtr:id>e29080962d481ae8af4509c5a8c39045</gtr:id><gtr:otherNames>Frame FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F3F766B-6CAE-412A-BAD3-8DC4E3ACE5C2"><gtr:id>6F3F766B-6CAE-412A-BAD3-8DC4E3ACE5C2</gtr:id><gtr:title>The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7970604460f05c53478d7d8c09b1992f"><gtr:id>7970604460f05c53478d7d8c09b1992f</gtr:id><gtr:otherNames>Sharma NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/63CAF5BE-DEBB-4104-9AF4-D124530E9F99"><gtr:id>63CAF5BE-DEBB-4104-9AF4-D124530E9F99</gtr:id><gtr:title>Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3879ad10d1bd3ea7bcc9795bbb0ad5d6"><gtr:id>3879ad10d1bd3ea7bcc9795bbb0ad5d6</gtr:id><gtr:otherNames>Orozco G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DEBF3E06-DB3B-46AC-BEEB-4581C7520D26"><gtr:id>DEBF3E06-DB3B-46AC-BEEB-4581C7520D26</gtr:id><gtr:title>Evaluating baculovirus as a vector for human prostate cancer gene therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f0e2ed6972a34843914bec10d88f04a"><gtr:id>7f0e2ed6972a34843914bec10d88f04a</gtr:id><gtr:otherNames>Swift SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73CA2CCD-891D-4C18-8D0C-ACC2A9A88DBE"><gtr:id>73CA2CCD-891D-4C18-8D0C-ACC2A9A88DBE</gtr:id><gtr:title>Prostate cancer stem cells: do they have a basal or luminal phenotype?</gtr:title><gtr:parentPublicationTitle>Hormones &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eab58915d98e5a265b7a319493723193"><gtr:id>eab58915d98e5a265b7a319493723193</gtr:id><gtr:otherNames>Maitland NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1868-8497</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0A71395-A344-46C0-A567-2123350F4E16"><gtr:id>E0A71395-A344-46C0-A567-2123350F4E16</gtr:id><gtr:title>RAS pathways in prostate cancer - mediators of hormone resistance?</gtr:title><gtr:parentPublicationTitle>Current cancer drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1568-0096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE5421B3-795B-4DB0-A845-44B0CC76501B"><gtr:id>BE5421B3-795B-4DB0-A845-44B0CC76501B</gtr:id><gtr:title>Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/633fec4168528199523095e6649177c4"><gtr:id>633fec4168528199523095e6649177c4</gtr:id><gtr:otherNames>Mitchell T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29A3FD78-5086-497D-84DD-AFE40A1DC7FF"><gtr:id>29A3FD78-5086-497D-84DD-AFE40A1DC7FF</gtr:id><gtr:title>Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c72efa02271f20b50a9d5d80f2ea4cf3"><gtr:id>c72efa02271f20b50a9d5d80f2ea4cf3</gtr:id><gtr:otherNames>Ricci E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B444962F-CD63-4B4A-B2AB-43B95B85747B"><gtr:id>B444962F-CD63-4B4A-B2AB-43B95B85747B</gtr:id><gtr:title>The ETS family member GABPa modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7970604460f05c53478d7d8c09b1992f"><gtr:id>7970604460f05c53478d7d8c09b1992f</gtr:id><gtr:otherNames>Sharma NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F86FD7C5-F575-4A70-8BFF-851286F7A962"><gtr:id>F86FD7C5-F575-4A70-8BFF-851286F7A962</gtr:id><gtr:title>Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9655c5b98308c8c1ce059d3c942d91be"><gtr:id>9655c5b98308c8c1ce059d3c942d91be</gtr:id><gtr:otherNames>Hayami S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA5F7841-32EE-4B1B-8AC1-57BD84AFA715"><gtr:id>FA5F7841-32EE-4B1B-8AC1-57BD84AFA715</gtr:id><gtr:title>Words of wisdom: re: prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eab58915d98e5a265b7a319493723193"><gtr:id>eab58915d98e5a265b7a319493723193</gtr:id><gtr:otherNames>Maitland NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4F69E092-5FE3-497C-8EDD-A4E01E078EC5"><gtr:id>4F69E092-5FE3-497C-8EDD-A4E01E078EC5</gtr:id><gtr:title>In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d3497eb3871cc51efc1e60a241fde37d"><gtr:id>d3497eb3871cc51efc1e60a241fde37d</gtr:id><gtr:otherNames>Adamson RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FEA89AC1-C859-4426-BF89-62C0FEB8917B"><gtr:id>FEA89AC1-C859-4426-BF89-62C0FEB8917B</gtr:id><gtr:title>Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/042b3e90146043230abd551b4b579fc3"><gtr:id>042b3e90146043230abd551b4b579fc3</gtr:id><gtr:otherNames>Armstrong K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D037CC0-D095-4896-A294-08C282500636"><gtr:id>9D037CC0-D095-4896-A294-08C282500636</gtr:id><gtr:title>Regulation of the androgen receptor by SET9-mediated methylation.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d33bf1e67bab06e27a4ff2aa938b3921"><gtr:id>d33bf1e67bab06e27a4ff2aa938b3921</gtr:id><gtr:otherNames>Gaughan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24C97F51-2F02-4B74-B4D2-9DFCD985D1F9"><gtr:id>24C97F51-2F02-4B74-B4D2-9DFCD985D1F9</gtr:id><gtr:title>The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43df6c3b064686cdaee08e60cef0c89f"><gtr:id>43df6c3b064686cdaee08e60cef0c89f</gtr:id><gtr:otherNames>Catto JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E36AAF99-4B6F-4646-A8B0-633A93FCC4E8"><gtr:id>E36AAF99-4B6F-4646-A8B0-633A93FCC4E8</gtr:id><gtr:title>The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42f82449a2b9f27ce959a47327c4da62"><gtr:id>42f82449a2b9f27ce959a47327c4da62</gtr:id><gtr:otherNames>Massie CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53A58B0E-9D41-4C53-BF99-9E016AC31D58"><gtr:id>53A58B0E-9D41-4C53-BF99-9E016AC31D58</gtr:id><gtr:title>Clinical adenoviral gene therapy for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ecf518be099b70354271841f4e009b58"><gtr:id>ecf518be099b70354271841f4e009b58</gtr:id><gtr:otherNames>Schenk E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B246FC1-543D-41AB-A6BD-C3E7C9E057F7"><gtr:id>6B246FC1-543D-41AB-A6BD-C3E7C9E057F7</gtr:id><gtr:title>Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98bed1be640b4a077870bdc03d61676d"><gtr:id>98bed1be640b4a077870bdc03d61676d</gtr:id><gtr:otherNames>Burton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34009D08-1755-402F-A78D-7A9201639DE3"><gtr:id>34009D08-1755-402F-A78D-7A9201639DE3</gtr:id><gtr:title>Phenotypic effects of HPV-16 E2 protein expression in human keratinocytes.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c5234e4320dddff4335e363ef0b0954"><gtr:id>5c5234e4320dddff4335e363ef0b0954</gtr:id><gtr:otherNames>Burns JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/371FDFF1-3756-4C96-BB0A-3E50CB62B192"><gtr:id>371FDFF1-3756-4C96-BB0A-3E50CB62B192</gtr:id><gtr:title>Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e14f6924e8f2de2ef38ea52a993768cd"><gtr:id>e14f6924e8f2de2ef38ea52a993768cd</gtr:id><gtr:otherNames>Pashayan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7E44E34-1C7E-4E31-B10E-7308F645A87B"><gtr:id>B7E44E34-1C7E-4E31-B10E-7308F645A87B</gtr:id><gtr:title>Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b743b645113d9bc4943b626810730b34"><gtr:id>b743b645113d9bc4943b626810730b34</gtr:id><gtr:otherNames>Lyratzopoulos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/110B5929-C7B2-4A54-909F-753C3CAB38FB"><gtr:id>110B5929-C7B2-4A54-909F-753C3CAB38FB</gtr:id><gtr:title>No evidence for infection of UK prostate cancer patients with XMRV, BK virus, Trichomonas vaginalis or human papilloma viruses.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB8804C2-B718-4A4F-9328-D1F3715AEA32"><gtr:id>BB8804C2-B718-4A4F-9328-D1F3715AEA32</gtr:id><gtr:title>Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7235e5f5ce957c2b1c0b67bac2db4a3"><gtr:id>e7235e5f5ce957c2b1c0b67bac2db4a3</gtr:id><gtr:otherNames>Grisanzio C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3F7D841D-1493-486A-9963-BC438588955F"><gtr:id>3F7D841D-1493-486A-9963-BC438588955F</gtr:id><gtr:title>Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3422bff85833b78d82608129bd677905"><gtr:id>3422bff85833b78d82608129bd677905</gtr:id><gtr:otherNames>Williams N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A713E209-670E-4706-95ED-BB1183D0A5BB"><gtr:id>A713E209-670E-4706-95ED-BB1183D0A5BB</gtr:id><gtr:title>A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7bcfe6bc5eafd47514c917314a7dc3fd"><gtr:id>7bcfe6bc5eafd47514c917314a7dc3fd</gtr:id><gtr:otherNames>Al Olama AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04C6EEEF-A3A9-4C56-8B33-DBC06C0E143E"><gtr:id>04C6EEEF-A3A9-4C56-8B33-DBC06C0E143E</gtr:id><gtr:title>Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ba75dc69144818b02846de1303bf67a5"><gtr:id>ba75dc69144818b02846de1303bf67a5</gtr:id><gtr:otherNames>Coffey K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/125471D6-1266-4C5F-9897-A4974A986693"><gtr:id>125471D6-1266-4C5F-9897-A4974A986693</gtr:id><gtr:title>Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cd753fda3bce2547bbdf1a5e6b8c20d2"><gtr:id>cd753fda3bce2547bbdf1a5e6b8c20d2</gtr:id><gtr:otherNames>Lane JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB3BACFA-EFBB-43D8-881C-C22F7094D762"><gtr:id>EB3BACFA-EFBB-43D8-881C-C22F7094D762</gtr:id><gtr:title>Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1927e83ba5abd3172a2da8443707f366"><gtr:id>1927e83ba5abd3172a2da8443707f366</gtr:id><gtr:otherNames>Madden T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/08F7CECF-E164-4393-809B-C0AD446A8987"><gtr:id>08F7CECF-E164-4393-809B-C0AD446A8987</gtr:id><gtr:title>Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e1ab7734abf705955e212abd5cc7c001"><gtr:id>e1ab7734abf705955e212abd5cc7c001</gtr:id><gtr:otherNames>Jurmeister S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDDB313A-A0EE-46DF-BF23-C9C555327BE9"><gtr:id>EDDB313A-A0EE-46DF-BF23-C9C555327BE9</gtr:id><gtr:title>Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/70862736759c7f4aeb94a67cf6dbe7a2"><gtr:id>70862736759c7f4aeb94a67cf6dbe7a2</gtr:id><gtr:otherNames>Gilbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1ADE8248-C868-4EF1-AA26-327F43F9F733"><gtr:id>1ADE8248-C868-4EF1-AA26-327F43F9F733</gtr:id><gtr:title>Thiol isomerases negatively regulate the cellular shedding activity of ADAM17.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/96d82f99b8ef904502a8501b7d912194"><gtr:id>96d82f99b8ef904502a8501b7d912194</gtr:id><gtr:otherNames>Willems SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC0CCFFC-0231-4629-BD8E-3CD731C71AA8"><gtr:id>EC0CCFFC-0231-4629-BD8E-3CD731C71AA8</gtr:id><gtr:title>Metabolic imbalance and prostate cancer progression.</gtr:title><gtr:parentPublicationTitle>International journal of molecular epidemiology and genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb77305aa7098b4b98ad773503d483c"><gtr:id>2fb77305aa7098b4b98ad773503d483c</gtr:id><gtr:otherNames>Burton AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1948-1756</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C7822D7B-9512-4BDC-BB88-EA4E711AC8FC"><gtr:id>C7822D7B-9512-4BDC-BB88-EA4E711AC8FC</gtr:id><gtr:title>Understanding surgical interventions in RCTs: the need for better methodology.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6991770736449cc3190b4c13d1e92c2"><gtr:id>f6991770736449cc3190b4c13d1e92c2</gtr:id><gtr:otherNames>Avery KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54493E76-0B17-4009-9798-CC85BF9C9694"><gtr:id>54493E76-0B17-4009-9798-CC85BF9C9694</gtr:id><gtr:title>Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2fb77305aa7098b4b98ad773503d483c"><gtr:id>2fb77305aa7098b4b98ad773503d483c</gtr:id><gtr:otherNames>Burton AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25A3D4EF-0607-49DA-98D4-06B450009467"><gtr:id>25A3D4EF-0607-49DA-98D4-06B450009467</gtr:id><gtr:title>Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/17e12f0bf7b2d588d26d64444d86df65"><gtr:id>17e12f0bf7b2d588d26d64444d86df65</gtr:id><gtr:otherNames>Zecchini V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03533052-B604-46BC-BE1B-CDEFE51DC962"><gtr:id>03533052-B604-46BC-BE1B-CDEFE51DC962</gtr:id><gtr:title>The role of surgery in high-risk localised prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72313d0b4fb74aa7f876af123ebcad82"><gtr:id>72313d0b4fb74aa7f876af123ebcad82</gtr:id><gtr:otherNames>Gnanapragasam VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D81D212B-4C22-4AFB-B308-E9609827B776"><gtr:id>D81D212B-4C22-4AFB-B308-E9609827B776</gtr:id><gtr:title>Open to debate. The motion: GnRH antagonists are the new way forward in hormonal therapy.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5695006f0a14fdaa8b40cc87ee828535"><gtr:id>5695006f0a14fdaa8b40cc87ee828535</gtr:id><gtr:otherNames>Clarke NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3179EDA0-B5F9-493F-A794-4B8461470C06"><gtr:id>3179EDA0-B5F9-493F-A794-4B8461470C06</gtr:id><gtr:title>Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bdcebffa3bde4cde28943efefbeb46fb"><gtr:id>bdcebffa3bde4cde28943efefbeb46fb</gtr:id><gtr:otherNames>Zuccolo L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4FE02B2-7937-4C74-9120-A59B547A41CE"><gtr:id>D4FE02B2-7937-4C74-9120-A59B547A41CE</gtr:id><gtr:title>Ras mutation cooperates with ?-catenin activation to drive bladder tumourigenesis.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ca0f5e385ea7be4f8f9a44484558586"><gtr:id>5ca0f5e385ea7be4f8f9a44484558586</gtr:id><gtr:otherNames>Ahmad I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CD435106-1234-4692-8B06-5355D00EDA9F"><gtr:id>CD435106-1234-4692-8B06-5355D00EDA9F</gtr:id><gtr:title>Adenovirus-derived vectors for prostate cancer gene therapy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7cdf212534cb6d445224d1183414e22f"><gtr:id>7cdf212534cb6d445224d1183414e22f</gtr:id><gtr:otherNames>de Vrij J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E65D975-61AD-490B-B5EC-8B70DCB2376E"><gtr:id>0E65D975-61AD-490B-B5EC-8B70DCB2376E</gtr:id><gtr:title>Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e091bbf7b923b73231b11334cd319245"><gtr:id>e091bbf7b923b73231b11334cd319245</gtr:id><gtr:otherNames>Ankerst DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37EA93F3-6801-491A-A177-08CF35662D82"><gtr:id>37EA93F3-6801-491A-A177-08CF35662D82</gtr:id><gtr:title>Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c3ec56f911e322a2a9420afef435968"><gtr:id>3c3ec56f911e322a2a9420afef435968</gtr:id><gtr:otherNames>McLean MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2997B217-3E5B-4208-802A-2012E22011D9"><gtr:id>2997B217-3E5B-4208-802A-2012E22011D9</gtr:id><gtr:title>Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ee9cbc7c01c38f14f79036724935e50e"><gtr:id>ee9cbc7c01c38f14f79036724935e50e</gtr:id><gtr:otherNames>Groselj B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CDA09627-0025-4E92-AC8B-CEE994D40F69"><gtr:id>CDA09627-0025-4E92-AC8B-CEE994D40F69</gtr:id><gtr:title>SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3481efaa85ff4ab90b91befb940ddeee"><gtr:id>3481efaa85ff4ab90b91befb940ddeee</gtr:id><gtr:otherNames>Hughes C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF2C62F5-410A-41B1-8808-50DC139ABBA9"><gtr:id>AF2C62F5-410A-41B1-8808-50DC139ABBA9</gtr:id><gtr:title>The recruitment of patients to trials in head and neck cancer: a qualitative study of the EaStER trial of treatments for early laryngeal cancer.</gtr:title><gtr:parentPublicationTitle>European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5e914029aba5da03395a498cd4a9dcd"><gtr:id>c5e914029aba5da03395a498cd4a9dcd</gtr:id><gtr:otherNames>Hamilton DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0937-4477</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F3AA5E3C-3CDB-4A56-B56B-0583D5806B3A"><gtr:id>F3AA5E3C-3CDB-4A56-B56B-0583D5806B3A</gtr:id><gtr:title>Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b53a7d34e764e15ac71d5b2c6b2be4d"><gtr:id>1b53a7d34e764e15ac71d5b2c6b2be4d</gtr:id><gtr:otherNames>Ramani VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46C73F25-83E5-49DF-B2FD-9A249D60D1D6"><gtr:id>46C73F25-83E5-49DF-B2FD-9A249D60D1D6</gtr:id><gtr:title>Imaging angiogenesis of genitourinary tumors.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/95114ba6b9e8321e1dafa232fbe4aa7c"><gtr:id>95114ba6b9e8321e1dafa232fbe4aa7c</gtr:id><gtr:otherNames>Zee YK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AECC9CDC-28C9-436C-B127-FA1A3FC30F7C"><gtr:id>AECC9CDC-28C9-436C-B127-FA1A3FC30F7C</gtr:id><gtr:title>Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.</gtr:title><gtr:parentPublicationTitle>Clinical therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24f442f9671c4349c22779761cf84cb7"><gtr:id>24f442f9671c4349c22779761cf84cb7</gtr:id><gtr:otherNames>Malloy RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0149-2918</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22A1C974-3C81-46F6-9F54-BA707F88B7AF"><gtr:id>22A1C974-3C81-46F6-9F54-BA707F88B7AF</gtr:id><gtr:title>Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4511055f60c4484160df59970fa7167c"><gtr:id>4511055f60c4484160df59970fa7167c</gtr:id><gtr:otherNames>Townes CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/45699556-416C-4B76-ABD0-29087334ADE4"><gtr:id>45699556-416C-4B76-ABD0-29087334ADE4</gtr:id><gtr:title>Androgen deprivation treatment in prostate cancer.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f40708e5cb9a67fd8bd513003f7ae16d"><gtr:id>f40708e5cb9a67fd8bd513003f7ae16d</gtr:id><gtr:otherNames>Thomas BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D90C8970-84A4-43BC-8684-79140FD86E67"><gtr:id>D90C8970-84A4-43BC-8684-79140FD86E67</gtr:id><gtr:title>N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/956141D2-E917-4B5B-B936-3607001C87A1"><gtr:id>956141D2-E917-4B5B-B936-3607001C87A1</gtr:id><gtr:title>Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/17e12f0bf7b2d588d26d64444d86df65"><gtr:id>17e12f0bf7b2d588d26d64444d86df65</gtr:id><gtr:otherNames>Zecchini V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00C19839-3453-49CE-865A-550749C7E31C"><gtr:id>00C19839-3453-49CE-865A-550749C7E31C</gtr:id><gtr:title>Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/606da7626b0cad2a974e48926490df52"><gtr:id>606da7626b0cad2a974e48926490df52</gtr:id><gtr:otherNames>Hounsome LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ABEBAF93-674F-41A0-A678-6BEE03DA6E3B"><gtr:id>ABEBAF93-674F-41A0-A678-6BEE03DA6E3B</gtr:id><gtr:title>Long-term quality of life in prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a81d4ed931aa0b2389947fd9d7aa7143"><gtr:id>a81d4ed931aa0b2389947fd9d7aa7143</gtr:id><gtr:otherNames>Hamdy FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15B1FDF3-55F1-49C2-8A5C-3963B741BECB"><gtr:id>15B1FDF3-55F1-49C2-8A5C-3963B741BECB</gtr:id><gtr:title>Tumor necrosis factor receptor expression and signaling in renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b998be4188d5c8d563cef6a1110d03e9"><gtr:id>b998be4188d5c8d563cef6a1110d03e9</gtr:id><gtr:otherNames>Al-Lamki RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C4DCB396-A9EA-4A3A-A8AC-DCEE4D457ED9"><gtr:id>C4DCB396-A9EA-4A3A-A8AC-DCEE4D457ED9</gtr:id><gtr:title>Gleason drift in the NIHR ProtecT study.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fe97f1f38293f1ddac96857ea6ec8588"><gtr:id>fe97f1f38293f1ddac96857ea6ec8588</gtr:id><gtr:otherNames>Oxley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF0D200B-E14E-48A8-BA50-31E38B45A789"><gtr:id>FF0D200B-E14E-48A8-BA50-31E38B45A789</gtr:id><gtr:title>An investigation of the RWPE prostate derived family of cell lines using FTIR spectroscopy.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32bd6acdb52d21bf5f76cc1afe82eb5c"><gtr:id>32bd6acdb52d21bf5f76cc1afe82eb5c</gtr:id><gtr:otherNames>Baker MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7CF9718A-34A7-4742-95B5-A9E6BA5D34C6"><gtr:id>7CF9718A-34A7-4742-95B5-A9E6BA5D34C6</gtr:id><gtr:title>Small renal mass biopsy--how, what and when: report from an international consensus panel.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1d7b7e2e0ebc70a28330ab6a31415b0c"><gtr:id>1d7b7e2e0ebc70a28330ab6a31415b0c</gtr:id><gtr:otherNames>Tsivian M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB04D321-5B92-4074-B9F4-830B5A4513C9"><gtr:id>AB04D321-5B92-4074-B9F4-830B5A4513C9</gtr:id><gtr:title>A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71b9d72bc7c8a96fb10e4bae3fd80112"><gtr:id>71b9d72bc7c8a96fb10e4bae3fd80112</gtr:id><gtr:otherNames>Amin Al Olama A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94FE4561-886A-4133-9F6A-DE0E6F2E2E9E"><gtr:id>94FE4561-886A-4133-9F6A-DE0E6F2E2E9E</gtr:id><gtr:title>Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ae12619f0c581dfc462a0e0cb5313755"><gtr:id>ae12619f0c581dfc462a0e0cb5313755</gtr:id><gtr:otherNames>Arsov C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2691F6C0-988C-472B-AE74-957B168981C5"><gtr:id>2691F6C0-988C-472B-AE74-957B168981C5</gtr:id><gtr:title>Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3AA065A8-F97B-499F-B216-745CCD32968B"><gtr:id>3AA065A8-F97B-499F-B216-745CCD32968B</gtr:id><gtr:title>Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b743b645113d9bc4943b626810730b34"><gtr:id>b743b645113d9bc4943b626810730b34</gtr:id><gtr:otherNames>Lyratzopoulos G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/67A6A9CA-CE1F-4F4A-95C1-4310DE939CDA"><gtr:id>67A6A9CA-CE1F-4F4A-95C1-4310DE939CDA</gtr:id><gtr:title>Natural products: potential for developing Phellodendron amurense bark extract for prostate cancer management.</gtr:title><gtr:parentPublicationTitle>Mini reviews in medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d96c074949171b0b1c64a57ed0851ef"><gtr:id>4d96c074949171b0b1c64a57ed0851ef</gtr:id><gtr:otherNames>Kumar AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1389-5575</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BDDD84A6-99A0-424A-9E85-66EDBF30B85C"><gtr:id>BDDD84A6-99A0-424A-9E85-66EDBF30B85C</gtr:id><gtr:title>Men with prostate cancer make positive dietary changes following diagnosis and treatment.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6991770736449cc3190b4c13d1e92c2"><gtr:id>f6991770736449cc3190b4c13d1e92c2</gtr:id><gtr:otherNames>Avery KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7F84157-6D0C-497D-8D5F-5B7CC75F5972"><gtr:id>B7F84157-6D0C-497D-8D5F-5B7CC75F5972</gtr:id><gtr:title>Differential C3NET reveals disease networks of direct physical interactions.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d14b439198589ffae3e3c91a4756b47"><gtr:id>0d14b439198589ffae3e3c91a4756b47</gtr:id><gtr:otherNames>Altay G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28943323-A236-446D-92F0-8CB1FE41D117"><gtr:id>28943323-A236-446D-92F0-8CB1FE41D117</gtr:id><gtr:title>A fusion at the root of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Asian journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eab58915d98e5a265b7a319493723193"><gtr:id>eab58915d98e5a265b7a319493723193</gtr:id><gtr:otherNames>Maitland NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1008-682X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/615FCCF7-1CF6-44E8-9EBE-FD33DC7EA9F4"><gtr:id>615FCCF7-1CF6-44E8-9EBE-FD33DC7EA9F4</gtr:id><gtr:title>A comparison of prostate cancer survival in England, Norway and Sweden: a population-based study.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b0714c5cdf3584df35c962e5017636a7"><gtr:id>b0714c5cdf3584df35c962e5017636a7</gtr:id><gtr:otherNames>Holmberg L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1877-7821</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD4CA868-DB5C-48FB-AF00-3B31BAAE763B"><gtr:id>BD4CA868-DB5C-48FB-AF00-3B31BAAE763B</gtr:id><gtr:title>PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e14f6924e8f2de2ef38ea52a993768cd"><gtr:id>e14f6924e8f2de2ef38ea52a993768cd</gtr:id><gtr:otherNames>Pashayan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D44A5509-66D2-43F9-A90E-3CCA6AAA550A"><gtr:id>D44A5509-66D2-43F9-A90E-3CCA6AAA550A</gtr:id><gtr:title>Androgen regulates ADAMTS15 gene expression in prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Cancer investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42e2d072bfe36fa853cbaf4c2c88977e"><gtr:id>42e2d072bfe36fa853cbaf4c2c88977e</gtr:id><gtr:otherNames>Molokwu CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0735-7907</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1F18301-E4E2-4163-8BA5-4368674D9D1B"><gtr:id>F1F18301-E4E2-4163-8BA5-4368674D9D1B</gtr:id><gtr:title>The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer.</gtr:title><gtr:parentPublicationTitle>ANZ journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e82f9147d3c319d359cad874904fc3b"><gtr:id>3e82f9147d3c319d359cad874904fc3b</gtr:id><gtr:otherNames>Johnston R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1445-1433</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64A405F6-8555-4342-B903-7783FF4BE3BC"><gtr:id>64A405F6-8555-4342-B903-7783FF4BE3BC</gtr:id><gtr:title>Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/70862736759c7f4aeb94a67cf6dbe7a2"><gtr:id>70862736759c7f4aeb94a67cf6dbe7a2</gtr:id><gtr:otherNames>Gilbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB6C3188-864A-4904-A9C3-C57AA71C48C7"><gtr:id>DB6C3188-864A-4904-A9C3-C57AA71C48C7</gtr:id><gtr:title>Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F79D4D05-0AF0-4E22-81D0-04A91EC038CC"><gtr:id>F79D4D05-0AF0-4E22-81D0-04A91EC038CC</gtr:id><gtr:title>Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9655c5b98308c8c1ce059d3c942d91be"><gtr:id>9655c5b98308c8c1ce059d3c942d91be</gtr:id><gtr:otherNames>Hayami S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C8A7C60-32D1-45FD-83F9-E6735C5A5496"><gtr:id>3C8A7C60-32D1-45FD-83F9-E6735C5A5496</gtr:id><gtr:title>Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43df6c3b064686cdaee08e60cef0c89f"><gtr:id>43df6c3b064686cdaee08e60cef0c89f</gtr:id><gtr:otherNames>Catto JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7951E00C-1846-42AB-BCC7-AAD5ACB3E4A3"><gtr:id>7951E00C-1846-42AB-BCC7-AAD5ACB3E4A3</gtr:id><gtr:title>Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6732957518834465fb7cfe86c46c25fb"><gtr:id>6732957518834465fb7cfe86c46c25fb</gtr:id><gtr:otherNames>Xiong T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D853808C-4A4E-4295-91FB-44FA26A2FB34"><gtr:id>D853808C-4A4E-4295-91FB-44FA26A2FB34</gtr:id><gtr:title>[Active surveillance for localized prostate cancer].</gtr:title><gtr:parentPublicationTitle>Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff81e2cc45f55f998b38e10a88c75554"><gtr:id>ff81e2cc45f55f998b38e10a88c75554</gtr:id><gtr:otherNames>Drouin SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1166-7087</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/56909F36-E26A-4158-B1C1-BD132D50A4B6"><gtr:id>56909F36-E26A-4158-B1C1-BD132D50A4B6</gtr:id><gtr:title>Prominin-1 (CD133) Expression in the Prostate and Prostate Cancer: A Marker for Quiescent Stem Cells.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e22672178cb4a13bf6e9b12358c57e4c"><gtr:id>e22672178cb4a13bf6e9b12358c57e4c</gtr:id><gtr:otherNames>Pellacani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/817E53DF-C1EE-43BE-8B12-1F85BE11BE70"><gtr:id>817E53DF-C1EE-43BE-8B12-1F85BE11BE70</gtr:id><gtr:title>Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2a333852b12ae61c8a1a8d4c48746da9"><gtr:id>2a333852b12ae61c8a1a8d4c48746da9</gtr:id><gtr:otherNames>Johnson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9A1CA15-18E7-4892-893F-260412EDA378"><gtr:id>F9A1CA15-18E7-4892-893F-260412EDA378</gtr:id><gtr:title>Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/70862736759c7f4aeb94a67cf6dbe7a2"><gtr:id>70862736759c7f4aeb94a67cf6dbe7a2</gtr:id><gtr:otherNames>Gilbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/118F3C58-A3E9-48CD-A980-C54318909662"><gtr:id>118F3C58-A3E9-48CD-A980-C54318909662</gtr:id><gtr:title>Cancer stem cells, models of study and implications of therapy resistance mechanisms.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e29080962d481ae8af4509c5a8c39045"><gtr:id>e29080962d481ae8af4509c5a8c39045</gtr:id><gtr:otherNames>Frame FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CCB3BFD4-72E8-4244-B63D-3E234B8AAFFD"><gtr:id>CCB3BFD4-72E8-4244-B63D-3E234B8AAFFD</gtr:id><gtr:title>K-Ras and ?-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ca0f5e385ea7be4f8f9a44484558586"><gtr:id>5ca0f5e385ea7be4f8f9a44484558586</gtr:id><gtr:otherNames>Ahmad I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9A0F66F-7E09-44DE-AB98-0D481ABADB60"><gtr:id>E9A0F66F-7E09-44DE-AB98-0D481ABADB60</gtr:id><gtr:title>Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0348a972f4ea2d410cfc22663aafad64"><gtr:id>0348a972f4ea2d410cfc22663aafad64</gtr:id><gtr:otherNames>Lose F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/956CA4D6-C800-4DAC-BB50-07250CD411BD"><gtr:id>956CA4D6-C800-4DAC-BB50-07250CD411BD</gtr:id><gtr:title>DNA damage response in peritumoral regions of oesophageal cancer microenvironment.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7df34fe32c587ded57dd257cebc81430"><gtr:id>7df34fe32c587ded57dd257cebc81430</gtr:id><gtr:otherNames>He H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/32ECEE98-DD2F-40AE-80BF-B412234EB6D6"><gtr:id>32ECEE98-DD2F-40AE-80BF-B412234EB6D6</gtr:id><gtr:title>Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f0e2ed6972a34843914bec10d88f04a"><gtr:id>7f0e2ed6972a34843914bec10d88f04a</gtr:id><gtr:otherNames>Swift SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4589FDDB-508A-46C1-BABB-7C73F3F746A4"><gtr:id>4589FDDB-508A-46C1-BABB-7C73F3F746A4</gtr:id><gtr:title>Targeting the DNA double strand break repair machinery in prostate cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b2b0adef03f787668da195c394b18f93"><gtr:id>b2b0adef03f787668da195c394b18f93</gtr:id><gtr:otherNames>Shaheen FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5DA48A6B-1760-4185-8BBE-CA1C9D9C4CB1"><gtr:id>5DA48A6B-1760-4185-8BBE-CA1C9D9C4CB1</gtr:id><gtr:title>Very low PSA concentrations and deletions of the KLK3 gene.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc83b94d1f800e6c596d0df5a7553aa2"><gtr:id>cc83b94d1f800e6c596d0df5a7553aa2</gtr:id><gtr:otherNames>Rodriguez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78AD2463-0534-4583-A477-7101A4A9808E"><gtr:id>78AD2463-0534-4583-A477-7101A4A9808E</gtr:id><gtr:title>A versatile gene trap to visualize and interrogate the function of the vertebrate proteome.</gtr:title><gtr:parentPublicationTitle>Genes &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50f9d992674309cbb4d2510e36854818"><gtr:id>50f9d992674309cbb4d2510e36854818</gtr:id><gtr:otherNames>Trinh le A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0890-9369</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D5D69B4-4E37-476F-B1C9-0E37FEE1890F"><gtr:id>2D5D69B4-4E37-476F-B1C9-0E37FEE1890F</gtr:id><gtr:title>The association of diagnosis in the private or NHS sector on prostate cancer stage and treatment.</gtr:title><gtr:parentPublicationTitle>Journal of public health (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/30086fe83c1cb66b447e000cfd03199c"><gtr:id>30086fe83c1cb66b447e000cfd03199c</gtr:id><gtr:otherNames>Barbiere JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1741-3842</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6D4CFC50-11B6-403B-913E-6A52330E2F31"><gtr:id>6D4CFC50-11B6-403B-913E-6A52330E2F31</gtr:id><gtr:title>Transurethral resection biopsy as part of a saturation biopsy protocol: a cohort study and review of the literature.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0806dab47ca493c318d0ef78e407c8dd"><gtr:id>0806dab47ca493c318d0ef78e407c8dd</gtr:id><gtr:otherNames>Yates DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/590FFEE7-F76B-4AE4-A0CC-49709C3BAE79"><gtr:id>590FFEE7-F76B-4AE4-A0CC-49709C3BAE79</gtr:id><gtr:title>A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b9404f921c512f7ca056ab8d2ad96f2c"><gtr:id>b9404f921c512f7ca056ab8d2ad96f2c</gtr:id><gtr:otherNames>Magnusson MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E25303F4-2C58-449F-994F-BAE8D569297A"><gtr:id>E25303F4-2C58-449F-994F-BAE8D569297A</gtr:id><gtr:title>Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f830a256cf28c5d5a9a9781e1d0d8117"><gtr:id>f830a256cf28c5d5a9a9781e1d0d8117</gtr:id><gtr:otherNames>Rowlands MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A12D585E-63D7-4BC4-812A-BF6C27F9544C"><gtr:id>A12D585E-63D7-4BC4-812A-BF6C27F9544C</gtr:id><gtr:title>Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f1d2ce97cf22483e13b10ff3a15addf"><gtr:id>6f1d2ce97cf22483e13b10ff3a15addf</gtr:id><gtr:otherNames>Lang SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/83FAADC8-90E0-4D7C-B102-34F9226FCB95"><gtr:id>83FAADC8-90E0-4D7C-B102-34F9226FCB95</gtr:id><gtr:title>HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5ca0f5e385ea7be4f8f9a44484558586"><gtr:id>5ca0f5e385ea7be4f8f9a44484558586</gtr:id><gtr:otherNames>Ahmad I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B543600-B68B-41EF-A9A8-4413206DE376"><gtr:id>6B543600-B68B-41EF-A9A8-4413206DE376</gtr:id><gtr:title>A preclinical xenograft model of prostate cancer using human tumors.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ebcfd90fb1f945eab24a68df4de95e2d"><gtr:id>ebcfd90fb1f945eab24a68df4de95e2d</gtr:id><gtr:otherNames>Lawrence MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/073CE633-AAA5-4DB2-A5E6-79639E78A923"><gtr:id>073CE633-AAA5-4DB2-A5E6-79639E78A923</gtr:id><gtr:title>Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems?</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14c31a2f8940f68bcaa406a38f4e4e3a"><gtr:id>14c31a2f8940f68bcaa406a38f4e4e3a</gtr:id><gtr:otherNames>Maitland N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4134A64A-F40B-46D9-B8C0-F608A6F0980A"><gtr:id>4134A64A-F40B-46D9-B8C0-F608A6F0980A</gtr:id><gtr:title>Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/53211a193beb4422cc08dbc7f918bf07"><gtr:id>53211a193beb4422cc08dbc7f918bf07</gtr:id><gtr:otherNames>Polson ES</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1D1368FD-2B6E-4A53-9984-7C3431905766"><gtr:id>1D1368FD-2B6E-4A53-9984-7C3431905766</gtr:id><gtr:title>Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4e687e7e62db23388559e46d798d39c"><gtr:id>f4e687e7e62db23388559e46d798d39c</gtr:id><gtr:otherNames>Eeles RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/72B23B13-2B50-496F-89D0-5EBB3BE57767"><gtr:id>72B23B13-2B50-496F-89D0-5EBB3BE57767</gtr:id><gtr:title>Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a01d328f82632d7dd44e264970c311e"><gtr:id>0a01d328f82632d7dd44e264970c311e</gtr:id><gtr:otherNames>Bennett HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C8093322-AE02-4BEF-9110-66D3BCBAB431"><gtr:id>C8093322-AE02-4BEF-9110-66D3BCBAB431</gtr:id><gtr:title>Re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009;56:1-9.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f112b93b25fc814d2a75ce2e8c4e2fba"><gtr:id>f112b93b25fc814d2a75ce2e8c4e2fba</gtr:id><gtr:otherNames>Palou J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2883A5EA-A57E-4F2D-845C-8A44A10B9997"><gtr:id>2883A5EA-A57E-4F2D-845C-8A44A10B9997</gtr:id><gtr:title>Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/17a67743217c77c807b10117f3f03613"><gtr:id>17a67743217c77c807b10117f3f03613</gtr:id><gtr:otherNames>Wiltshire C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D640DE7E-A3A5-449D-AF78-48FA918D52A8"><gtr:id>D640DE7E-A3A5-449D-AF78-48FA918D52A8</gtr:id><gtr:title>Androgen deprivation treatment in prostate cancer.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f40708e5cb9a67fd8bd513003f7ae16d"><gtr:id>f40708e5cb9a67fd8bd513003f7ae16d</gtr:id><gtr:otherNames>Thomas BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA38A76C-DFE5-460F-8326-C146D1F0BAD4"><gtr:id>CA38A76C-DFE5-460F-8326-C146D1F0BAD4</gtr:id><gtr:title>Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ac2826bcf23aa9dd242ed02d8851545"><gtr:id>0ac2826bcf23aa9dd242ed02d8851545</gtr:id><gtr:otherNames>Dudderidge TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E149E3EB-ED68-46D6-B438-27744E3D1AE8"><gtr:id>E149E3EB-ED68-46D6-B438-27744E3D1AE8</gtr:id><gtr:title>Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a01d328f82632d7dd44e264970c311e"><gtr:id>0a01d328f82632d7dd44e264970c311e</gtr:id><gtr:otherNames>Bennett HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85B5184B-4BD3-474E-9EA3-89E7389AA725"><gtr:id>85B5184B-4BD3-474E-9EA3-89E7389AA725</gtr:id><gtr:title>Reply from Authors re: Felix Wezel, Jennifer Southgate. Reprogramming Stromal Cells from the Urinary Tract and Prostate: A Trip to Pluripotency and Back? Eur Urol 2013;64:762-4</gtr:title><gtr:parentPublicationTitle>European Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f33cb7180f200fdc4295e29cb3d1db62"><gtr:id>f33cb7180f200fdc4295e29cb3d1db62</gtr:id><gtr:otherNames>Pal D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B3EFB7D-9987-44C6-A2D2-B257486B6662"><gtr:id>2B3EFB7D-9987-44C6-A2D2-B257486B6662</gtr:id><gtr:title>Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e14f6924e8f2de2ef38ea52a993768cd"><gtr:id>e14f6924e8f2de2ef38ea52a993768cd</gtr:id><gtr:otherNames>Pashayan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1877-7821</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA99D6DA-C931-4794-A7CB-93B4FE20AF2C"><gtr:id>DA99D6DA-C931-4794-A7CB-93B4FE20AF2C</gtr:id><gtr:title>General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8bf48815d8b94d92542d66cd2d2610eb"><gtr:id>8bf48815d8b94d92542d66cd2d2610eb</gtr:id><gtr:otherNames>Wong LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CB80135E-73A9-4F8B-9812-99369F84947C"><gtr:id>CB80135E-73A9-4F8B-9812-99369F84947C</gtr:id><gtr:title>The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ba75dc69144818b02846de1303bf67a5"><gtr:id>ba75dc69144818b02846de1303bf67a5</gtr:id><gtr:otherNames>Coffey K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CBC3FFB9-6E1D-4B25-B029-3A821ACD1A30"><gtr:id>CBC3FFB9-6E1D-4B25-B029-3A821ACD1A30</gtr:id><gtr:title>The calcium sensor STIM1 is regulated by androgens in prostate stromal cells.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/05c37759423ca8ce0e63b42366a856a6"><gtr:id>05c37759423ca8ce0e63b42366a856a6</gtr:id><gtr:otherNames>Berry PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9326E327-9EC3-4052-AC74-B5AC1E94D32F"><gtr:id>9326E327-9EC3-4052-AC74-B5AC1E94D32F</gtr:id><gtr:title>Mutation analysis of the MSMB gene in familial prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BD1B32FD-CE18-4641-860E-AEED395A2F6E"><gtr:id>BD1B32FD-CE18-4641-860E-AEED395A2F6E</gtr:id><gtr:title>PSA testing for prostate cancer improves survival--but can we do better?</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7508a3fb467e8c729a0bb445408afd01"><gtr:id>7508a3fb467e8c729a0bb445408afd01</gtr:id><gtr:otherNames>Neal DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC4309B3-2450-4F58-B916-F00835F8914F"><gtr:id>AC4309B3-2450-4F58-B916-F00835F8914F</gtr:id><gtr:title>Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f830a256cf28c5d5a9a9781e1d0d8117"><gtr:id>f830a256cf28c5d5a9a9781e1d0d8117</gtr:id><gtr:otherNames>Rowlands MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/831E767C-AD16-4ADD-B79E-40B2F92D4EFD"><gtr:id>831E767C-AD16-4ADD-B79E-40B2F92D4EFD</gtr:id><gtr:title>JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1860225a83f9d67168973604f3db3670"><gtr:id>1860225a83f9d67168973604f3db3670</gtr:id><gtr:otherNames>Kroon P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/948E7220-A746-4D59-A617-451427AEFFF1"><gtr:id>948E7220-A746-4D59-A617-451427AEFFF1</gtr:id><gtr:title>Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of cancer research and clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2621a32db445bc0c3f636ea893330950"><gtr:id>2621a32db445bc0c3f636ea893330950</gtr:id><gtr:otherNames>Hori S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0171-5216</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/160E24F0-DA72-4C7E-BF12-140E52B4036A"><gtr:id>160E24F0-DA72-4C7E-BF12-140E52B4036A</gtr:id><gtr:title>Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e79da553f4f5d957a0c70efd742c6829"><gtr:id>e79da553f4f5d957a0c70efd742c6829</gtr:id><gtr:otherNames>Glen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B3CC641-5136-470E-BCA0-EDBD048C1CEF"><gtr:id>6B3CC641-5136-470E-BCA0-EDBD048C1CEF</gtr:id><gtr:title>Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/655f5a810ed4a784d7e22f10bcd41e1d"><gtr:id>655f5a810ed4a784d7e22f10bcd41e1d</gtr:id><gtr:otherNames>Knipe DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43F3F9EF-DD7E-4AA4-873B-291446AFAED8"><gtr:id>43F3F9EF-DD7E-4AA4-873B-291446AFAED8</gtr:id><gtr:title>Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8eec587be914226f1bb19c5a4054d431"><gtr:id>8eec587be914226f1bb19c5a4054d431</gtr:id><gtr:otherNames>Wade J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF8B113B-6D61-4740-BC3C-479390CBC7C1"><gtr:id>FF8B113B-6D61-4740-BC3C-479390CBC7C1</gtr:id><gtr:title>RAS pathways in prostate cancer - mediators of hormone resistance?</gtr:title><gtr:parentPublicationTitle>Current cancer drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1568-0096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FAD7432E-0275-4804-B615-88D7241A72C5"><gtr:id>FAD7432E-0275-4804-B615-88D7241A72C5</gtr:id><gtr:title>Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/628381bad26bfa7f551e71a4f76aab58"><gtr:id>628381bad26bfa7f551e71a4f76aab58</gtr:id><gtr:otherNames>Bonilla C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB0C64F8-2920-4670-B27E-70D474C88787"><gtr:id>BB0C64F8-2920-4670-B27E-70D474C88787</gtr:id><gtr:title>Schisandrin B elicits a glutathione antioxidant response and protects against apoptosis via the redox-sensitive ERK/Nrf2 pathway in H9c2 cells.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f1e811d4e727de3d4e918a109eac898"><gtr:id>5f1e811d4e727de3d4e918a109eac898</gtr:id><gtr:otherNames>Chiu PY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-8177</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C2C07044-8BB1-4074-8F68-867E96E203C8"><gtr:id>C2C07044-8BB1-4074-8F68-867E96E203C8</gtr:id><gtr:title>Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aaafdd67273fc70bf1cee1eb1407ec7d"><gtr:id>aaafdd67273fc70bf1cee1eb1407ec7d</gtr:id><gtr:otherNames>de Brito LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AAED6F45-95BD-4A30-A8DB-4B2FD72DFE72"><gtr:id>AAED6F45-95BD-4A30-A8DB-4B2FD72DFE72</gtr:id><gtr:title>Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fb38dd2c1c90a8bbec025b677dec0f1e"><gtr:id>fb38dd2c1c90a8bbec025b677dec0f1e</gtr:id><gtr:otherNames>Turner EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C02738E5-6827-4BA2-AE62-90449090AB96"><gtr:id>C02738E5-6827-4BA2-AE62-90449090AB96</gtr:id><gtr:title>Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41b723d4a25538e6ae5d99c9e0e34a5a"><gtr:id>41b723d4a25538e6ae5d99c9e0e34a5a</gtr:id><gtr:otherNames>Morgan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/965D90E0-F014-499D-88B3-67B788F2793B"><gtr:id>965D90E0-F014-499D-88B3-67B788F2793B</gtr:id><gtr:title>Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3736f6faf812d35be9b1eab7b2410f87"><gtr:id>3736f6faf812d35be9b1eab7b2410f87</gtr:id><gtr:otherNames>Mitra AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/83F88670-F909-4211-81EF-17991411C8D2"><gtr:id>83F88670-F909-4211-81EF-17991411C8D2</gtr:id><gtr:title>Exploring treatment preferences facilitated recruitment to randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/131290eb61bf5bf74038ca79e8512782"><gtr:id>131290eb61bf5bf74038ca79e8512782</gtr:id><gtr:otherNames>Mills N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81DBA9EA-C46A-46EB-B868-218EF65680E6"><gtr:id>81DBA9EA-C46A-46EB-B868-218EF65680E6</gtr:id><gtr:title>Baculoviruses as gene therapy vectors for human prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of invertebrate pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88ef7c970dfe14e67f9c902d56cfd232"><gtr:id>88ef7c970dfe14e67f9c902d56cfd232</gtr:id><gtr:otherNames>Rivera-Gonzalez GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2011</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC8C6BBC-09EE-4CD9-8880-0DE611A9BDAB"><gtr:id>CC8C6BBC-09EE-4CD9-8880-0DE611A9BDAB</gtr:id><gtr:title>A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).</gtr:title><gtr:parentPublicationTitle>International journal of molecular epidemiology and genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b638530b850c3c62c3bf3445140b294e"><gtr:id>b638530b850c3c62c3bf3445140b294e</gtr:id><gtr:otherNames>Murad AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1948-1756</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55A71083-76BC-4F3E-8DE9-8AE9BD183A2A"><gtr:id>55A71083-76BC-4F3E-8DE9-8AE9BD183A2A</gtr:id><gtr:title>Early prostate cancer--which treatment do men prefer and why?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eba37908fa4d307f79bd31d0a8152631"><gtr:id>eba37908fa4d307f79bd31d0a8152631</gtr:id><gtr:otherNames>Anandadas CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E15AD72D-DAF8-43A7-A563-EF09EE10F959"><gtr:id>E15AD72D-DAF8-43A7-A563-EF09EE10F959</gtr:id><gtr:title>Method for sampling tissue for research which preserves pathological data in radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4f5ca2819e3d1f63b2d32138a7e14759"><gtr:id>4f5ca2819e3d1f63b2d32138a7e14759</gtr:id><gtr:otherNames>Warren AY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31495CF4-6EBC-4444-A437-524C5D3F85B7"><gtr:id>31495CF4-6EBC-4444-A437-524C5D3F85B7</gtr:id><gtr:title>Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ad757638bf6e6a427110748ca55cff7"><gtr:id>6ad757638bf6e6a427110748ca55cff7</gtr:id><gtr:otherNames>Dimitropoulou P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A2D577B-582E-4849-8E6C-5BED5CABBB0C"><gtr:id>0A2D577B-582E-4849-8E6C-5BED5CABBB0C</gtr:id><gtr:title>Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4204E04B-43F8-4048-8DED-896BB4347F09"><gtr:id>4204E04B-43F8-4048-8DED-896BB4347F09</gtr:id><gtr:title>Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/801393A9-FF38-45C3-996E-C3D9594DB092"><gtr:id>801393A9-FF38-45C3-996E-C3D9594DB092</gtr:id><gtr:title>DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68af30591ea79179094038aaf2a8f768"><gtr:id>68af30591ea79179094038aaf2a8f768</gtr:id><gtr:otherNames>Barrett T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1D93F196-92BF-4EA5-AB92-BC6FA44AE94E"><gtr:id>1D93F196-92BF-4EA5-AB92-BC6FA44AE94E</gtr:id><gtr:title>Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/37e65e52d827c7b8ce8916d425b5b7bc"><gtr:id>37e65e52d827c7b8ce8916d425b5b7bc</gtr:id><gtr:otherNames>Watson AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DEE777A-707A-4554-B3B3-95E36315E821"><gtr:id>8DEE777A-707A-4554-B3B3-95E36315E821</gtr:id><gtr:title>Prostate cancer stem cells.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f1d2ce97cf22483e13b10ff3a15addf"><gtr:id>6f1d2ce97cf22483e13b10ff3a15addf</gtr:id><gtr:otherNames>Lang SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EE975D6B-73C5-476E-8E70-B1BCF331EE75"><gtr:id>EE975D6B-73C5-476E-8E70-B1BCF331EE75</gtr:id><gtr:title>A NICE example? Variation in provision of bariatric surgery in England.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89924c9d427daf06c62189451f852835"><gtr:id>89924c9d427daf06c62189451f852835</gtr:id><gtr:otherNames>Owen-Smith A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D191C44B-ABDC-49DE-A514-1E48414E751B"><gtr:id>D191C44B-ABDC-49DE-A514-1E48414E751B</gtr:id><gtr:title>Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa7f1dc4fda8d5c0fa368f184b958645"><gtr:id>aa7f1dc4fda8d5c0fa368f184b958645</gtr:id><gtr:otherNames>Robinson JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/566552F3-BFE2-4E31-BA31-7BAC85B86577"><gtr:id>566552F3-BFE2-4E31-BA31-7BAC85B86577</gtr:id><gtr:title>Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/167eb8a3625e94923402fa33042243d6"><gtr:id>167eb8a3625e94923402fa33042243d6</gtr:id><gtr:otherNames>Tubio JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/380DF022-D20D-45CA-8C6C-8A0C550469F9"><gtr:id>380DF022-D20D-45CA-8C6C-8A0C550469F9</gtr:id><gtr:title>Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/547f807dc0ebfcdc83f554f5aca958ab"><gtr:id>547f807dc0ebfcdc83f554f5aca958ab</gtr:id><gtr:otherNames>Yu D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B12635E-0681-44A2-B1B7-6F63746FECFD"><gtr:id>4B12635E-0681-44A2-B1B7-6F63746FECFD</gtr:id><gtr:title>Curative radiation therapy in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Acta oncologica (Stockholm, Sweden)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/453cb3a1274dbb4dd5badc6fe356be7c"><gtr:id>453cb3a1274dbb4dd5badc6fe356be7c</gtr:id><gtr:otherNames>Harmenberg U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0284-186X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FA50EC9-CED0-4C05-9BB3-5EC0CACAEA83"><gtr:id>6FA50EC9-CED0-4C05-9BB3-5EC0CACAEA83</gtr:id><gtr:title>Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21cab1a100cc994e6c9417780528fdde"><gtr:id>21cab1a100cc994e6c9417780528fdde</gtr:id><gtr:otherNames>Ju YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C4B26F7-A798-41E3-B39E-44E11C07B135"><gtr:id>4C4B26F7-A798-41E3-B39E-44E11C07B135</gtr:id><gtr:title>A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/255c257ba4a7eb766061fa54bf2f8e76"><gtr:id>255c257ba4a7eb766061fa54bf2f8e76</gtr:id><gtr:otherNames>Stacey SN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3218A270-6FEB-4867-ABE0-FF6DB65517D3"><gtr:id>3218A270-6FEB-4867-ABE0-FF6DB65517D3</gtr:id><gtr:title>Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5DA9CFDD-30E6-4577-8131-9AA482D6C52E"><gtr:id>5DA9CFDD-30E6-4577-8131-9AA482D6C52E</gtr:id><gtr:title>Prostate cancer stem cells: are they androgen-responsive?</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2af53529d4c9b9937815c815e76fdfe5"><gtr:id>2af53529d4c9b9937815c815e76fdfe5</gtr:id><gtr:otherNames>Oldridge EE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3482CC95-3DA2-44E3-BDF3-87D82935A26D"><gtr:id>3482CC95-3DA2-44E3-BDF3-87D82935A26D</gtr:id><gtr:title>Use of macrophages to target therapeutic adenovirus to human prostate tumors.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/38926ea3ac0bbc1dd4d07f0ca56e7f93"><gtr:id>38926ea3ac0bbc1dd4d07f0ca56e7f93</gtr:id><gtr:otherNames>Muthana M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/846DDFE1-82B9-4561-A833-C6619FC119AE"><gtr:id>846DDFE1-82B9-4561-A833-C6619FC119AE</gtr:id><gtr:title>The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89c2874476ccb17712044a80d1aa92b2"><gtr:id>89c2874476ccb17712044a80d1aa92b2</gtr:id><gtr:otherNames>Vickers AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD7B4070-B6DC-422A-A59A-35E1B884C6B5"><gtr:id>FD7B4070-B6DC-422A-A59A-35E1B884C6B5</gtr:id><gtr:title>The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23e8c60a5de2f77ad87f88f40fb8fcc6"><gtr:id>23e8c60a5de2f77ad87f88f40fb8fcc6</gtr:id><gtr:otherNames>Chamberlain C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0780F44-BF6A-44E7-B2C3-56FA32585B96"><gtr:id>A0780F44-BF6A-44E7-B2C3-56FA32585B96</gtr:id><gtr:title>The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?</gtr:title><gtr:parentPublicationTitle>International journal of molecular epidemiology and genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1948-1756</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F8E64D5C-A4B7-4A3E-ADFB-714024DEA5AA"><gtr:id>F8E64D5C-A4B7-4A3E-ADFB-714024DEA5AA</gtr:id><gtr:title>Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf9aa0c74ef53570ec9af209bc9ba620"><gtr:id>cf9aa0c74ef53570ec9af209bc9ba620</gtr:id><gtr:otherNames>Dev H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C0EDF6A-7A89-480B-9AD9-EA382038BF19"><gtr:id>4C0EDF6A-7A89-480B-9AD9-EA382038BF19</gtr:id><gtr:title>GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0e24eac3740ceec2f0da0ffdacb54d0"><gtr:id>d0e24eac3740ceec2f0da0ffdacb54d0</gtr:id><gtr:otherNames>Tan SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E09E565-42D1-435B-8285-443A406DF179"><gtr:id>6E09E565-42D1-435B-8285-443A406DF179</gtr:id><gtr:title>HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0999d2a243be2076336e092ebe668058"><gtr:id>0999d2a243be2076336e092ebe668058</gtr:id><gtr:otherNames>Ramos-Montoya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F213268-25EA-428E-ACCD-58754CC3796F"><gtr:id>6F213268-25EA-428E-ACCD-58754CC3796F</gtr:id><gtr:title>p68/DdX5 supports ?-catenin &amp;amp; RNAP II during androgen receptor mediated transcription in prostate cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b27ff50d0bfaf49d2437a6da8c0342d6"><gtr:id>b27ff50d0bfaf49d2437a6da8c0342d6</gtr:id><gtr:otherNames>Clark EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1AA0D36D-5602-428B-9253-A57745A24BEB"><gtr:id>1AA0D36D-5602-428B-9253-A57745A24BEB</gtr:id><gtr:title>Is population screening for prostate cancer good or bad?</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5695006f0a14fdaa8b40cc87ee828535"><gtr:id>5695006f0a14fdaa8b40cc87ee828535</gtr:id><gtr:otherNames>Clarke NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E5FE63C-77D9-4551-8714-977610175D61"><gtr:id>7E5FE63C-77D9-4551-8714-977610175D61</gtr:id><gtr:title>Behavior theory for dietary interventions for cancer prevention: a systematic review of utilization and effectiveness in creating behavior change.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6991770736449cc3190b4c13d1e92c2"><gtr:id>f6991770736449cc3190b4c13d1e92c2</gtr:id><gtr:otherNames>Avery KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DBCD80FC-5F70-4C0F-98FC-9218ED6FE0A3"><gtr:id>DBCD80FC-5F70-4C0F-98FC-9218ED6FE0A3</gtr:id><gtr:title>Renal differentiation from adult spermatogonial stem cells.</gtr:title><gtr:parentPublicationTitle>Renal failure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/957b35b6411b395c9dec34a4ac6b4e71"><gtr:id>957b35b6411b395c9dec34a4ac6b4e71</gtr:id><gtr:otherNames>Heer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0886-022X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91D06BFE-68E8-4C76-89B5-2BA8BDE04E46"><gtr:id>91D06BFE-68E8-4C76-89B5-2BA8BDE04E46</gtr:id><gtr:title>Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f830a256cf28c5d5a9a9781e1d0d8117"><gtr:id>f830a256cf28c5d5a9a9781e1d0d8117</gtr:id><gtr:otherNames>Rowlands MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1E3CCB6-F7BD-4A4D-AFC0-7D5D8C16D71C"><gtr:id>D1E3CCB6-F7BD-4A4D-AFC0-7D5D8C16D71C</gtr:id><gtr:title>MicroRNA in prostate, bladder, and kidney cancer: a systematic review.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43df6c3b064686cdaee08e60cef0c89f"><gtr:id>43df6c3b064686cdaee08e60cef0c89f</gtr:id><gtr:otherNames>Catto JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/472421B9-22A2-4A0D-9092-D355E81EF6B9"><gtr:id>472421B9-22A2-4A0D-9092-D355E81EF6B9</gtr:id><gtr:title>Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1daa94abfc4fba5722eb5c4d2cab353f"><gtr:id>1daa94abfc4fba5722eb5c4d2cab353f</gtr:id><gtr:otherNames>Simpkin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F9F65A8-46AA-4A90-B9EA-FC27AB7C7C71"><gtr:id>2F9F65A8-46AA-4A90-B9EA-FC27AB7C7C71</gtr:id><gtr:title>Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f946258759afef44ed86fa72f7364d7"><gtr:id>9f946258759afef44ed86fa72f7364d7</gtr:id><gtr:otherNames>Ulukaya E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0FE8DF48-6449-40C6-A23A-5C4B69DDDD42"><gtr:id>0FE8DF48-6449-40C6-A23A-5C4B69DDDD42</gtr:id><gtr:title>The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7970604460f05c53478d7d8c09b1992f"><gtr:id>7970604460f05c53478d7d8c09b1992f</gtr:id><gtr:otherNames>Sharma NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/436F46BB-80D7-4C55-8D07-C96C93F80686"><gtr:id>436F46BB-80D7-4C55-8D07-C96C93F80686</gtr:id><gtr:title>KDM4B is a master regulator of the estrogen receptor signalling cascade.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d33bf1e67bab06e27a4ff2aa938b3921"><gtr:id>d33bf1e67bab06e27a4ff2aa938b3921</gtr:id><gtr:otherNames>Gaughan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/15D8ABD4-8B6E-4928-9750-C3CC72D1E09D"><gtr:id>15D8ABD4-8B6E-4928-9750-C3CC72D1E09D</gtr:id><gtr:title>Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55d4354f0c3923ea5aaa963b8dab36ab"><gtr:id>55d4354f0c3923ea5aaa963b8dab36ab</gtr:id><gtr:otherNames>Georgopoulos LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7882344C-9EBA-4B08-8478-7E7A3A5DD1B0"><gtr:id>7882344C-9EBA-4B08-8478-7E7A3A5DD1B0</gtr:id><gtr:title>Young adulthood body mass index and risk of cancer in later adulthood: historical cohort study.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98bed1be640b4a077870bdc03d61676d"><gtr:id>98bed1be640b4a077870bdc03d61676d</gtr:id><gtr:otherNames>Burton A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87EF8064-C678-4BC8-BCC2-00173D3C08C6"><gtr:id>87EF8064-C678-4BC8-BCC2-00173D3C08C6</gtr:id><gtr:title>Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88ac149523104bc6f39b0c1de3d152d1"><gtr:id>88ac149523104bc6f39b0c1de3d152d1</gtr:id><gtr:otherNames>Elliott KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/676965F7-A81F-4210-9020-55AB411F44AF"><gtr:id>676965F7-A81F-4210-9020-55AB411F44AF</gtr:id><gtr:title>Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring.</gtr:title><gtr:parentPublicationTitle>European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/70862736759c7f4aeb94a67cf6dbe7a2"><gtr:id>70862736759c7f4aeb94a67cf6dbe7a2</gtr:id><gtr:otherNames>Gilbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-8278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A5BB01D-E918-4746-8A79-F55D170A3F49"><gtr:id>7A5BB01D-E918-4746-8A79-F55D170A3F49</gtr:id><gtr:title>ERK5 signalling in prostate cancer promotes an invasive phenotype.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97c941e6447453a3d19c2272f2d74375"><gtr:id>97c941e6447453a3d19c2272f2d74375</gtr:id><gtr:otherNames>Ramsay AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C160B647-3AC5-413F-9DC6-73887830F2DA"><gtr:id>C160B647-3AC5-413F-9DC6-73887830F2DA</gtr:id><gtr:title>Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d05af7b1f3d52beece455090e63c2d25"><gtr:id>d05af7b1f3d52beece455090e63c2d25</gtr:id><gtr:otherNames>Brown MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4AD4B26C-197E-456F-8462-CE3BA317A8D7"><gtr:id>4AD4B26C-197E-456F-8462-CE3BA317A8D7</gtr:id><gtr:title>Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6f03e62217adcc049f7a47a7d515335"><gtr:id>f6f03e62217adcc049f7a47a7d515335</gtr:id><gtr:otherNames>Yoshimatsu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8D9C7A1D-9F7D-49B0-B175-D10221BC69E7"><gtr:id>8D9C7A1D-9F7D-49B0-B175-D10221BC69E7</gtr:id><gtr:title>Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3c0a8d4575bb24248692933f2becd7bb"><gtr:id>3c0a8d4575bb24248692933f2becd7bb</gtr:id><gtr:otherNames>Eaton CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E260BDB-166D-4099-8998-799C3721FF3B"><gtr:id>0E260BDB-166D-4099-8998-799C3721FF3B</gtr:id><gtr:title>Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88b838a053b0d9c90fe0e21947743d7d"><gtr:id>88b838a053b0d9c90fe0e21947743d7d</gtr:id><gtr:otherNames>Macefield RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26D8EF83-02A5-4650-B37A-3EC9E3B44D3D"><gtr:id>26D8EF83-02A5-4650-B37A-3EC9E3B44D3D</gtr:id><gtr:title>Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ee0f357a0e2776fd8425a5ea7834596"><gtr:id>0ee0f357a0e2776fd8425a5ea7834596</gtr:id><gtr:otherNames>Saunders EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5399AB7A-C9B2-49A1-9431-666D9DFE064E"><gtr:id>5399AB7A-C9B2-49A1-9431-666D9DFE064E</gtr:id><gtr:title>Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e22672178cb4a13bf6e9b12358c57e4c"><gtr:id>e22672178cb4a13bf6e9b12358c57e4c</gtr:id><gtr:otherNames>Pellacani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4873DA4D-1EC0-49D9-A1F7-81B4D646975B"><gtr:id>4873DA4D-1EC0-49D9-A1F7-81B4D646975B</gtr:id><gtr:title>Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b638530b850c3c62c3bf3445140b294e"><gtr:id>b638530b850c3c62c3bf3445140b294e</gtr:id><gtr:otherNames>Murad AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1E6D30B-181B-4753-B02C-56F9E54E8140"><gtr:id>B1E6D30B-181B-4753-B02C-56F9E54E8140</gtr:id><gtr:title>The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A564F1F8-3A1F-41A8-AD1E-9F68CC351EB7"><gtr:id>A564F1F8-3A1F-41A8-AD1E-9F68CC351EB7</gtr:id><gtr:title>Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43df6c3b064686cdaee08e60cef0c89f"><gtr:id>43df6c3b064686cdaee08e60cef0c89f</gtr:id><gtr:otherNames>Catto JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB8DF7BC-0341-46C6-84CB-FD8D1F383A6F"><gtr:id>EB8DF7BC-0341-46C6-84CB-FD8D1F383A6F</gtr:id><gtr:title>First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7970604460f05c53478d7d8c09b1992f"><gtr:id>7970604460f05c53478d7d8c09b1992f</gtr:id><gtr:otherNames>Sharma NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E90E8BD6-2D74-49FF-A110-C4C2F35BC8BC"><gtr:id>E90E8BD6-2D74-49FF-A110-C4C2F35BC8BC</gtr:id><gtr:title>&amp;quot;Let's get the best quality research we can&amp;quot;: public awareness and acceptance of consent to use existing data in health research: a systematic review and qualitative study.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fff82f7ec3943b2a6e49aa18d935e1f"><gtr:id>5fff82f7ec3943b2a6e49aa18d935e1f</gtr:id><gtr:otherNames>Hill EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C88E2A5-A61C-4D8C-879E-F945686A0CE9"><gtr:id>7C88E2A5-A61C-4D8C-879E-F945686A0CE9</gtr:id><gtr:title>High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/93f086a70431d1e0121d13a93f655c79"><gtr:id>93f086a70431d1e0121d13a93f655c79</gtr:id><gtr:otherNames>van den Hoogen C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D88638FA-C6D9-4F00-BE4C-E79C3CDB4F26"><gtr:id>D88638FA-C6D9-4F00-BE4C-E79C3CDB4F26</gtr:id><gtr:title>Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.</gtr:title><gtr:parentPublicationTitle>Human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0340-6717</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7AF92CE3-1EE5-4ED9-BEA7-C481ACC8EA65"><gtr:id>7AF92CE3-1EE5-4ED9-BEA7-C481ACC8EA65</gtr:id><gtr:title>Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1d85d7524356f6c21cc2d2fc42e1d5c3"><gtr:id>1d85d7524356f6c21cc2d2fc42e1d5c3</gtr:id><gtr:otherNames>Mitchell A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/01C277ED-B9C5-461D-8A4C-1D0EA3A869CC"><gtr:id>01C277ED-B9C5-461D-8A4C-1D0EA3A869CC</gtr:id><gtr:title>A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5bd59982d958b98e07a04f3ff14912bb"><gtr:id>5bd59982d958b98e07a04f3ff14912bb</gtr:id><gtr:otherNames>Young NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/37E78946-B125-4ACB-92E4-6880B5DA6AA5"><gtr:id>37E78946-B125-4ACB-92E4-6880B5DA6AA5</gtr:id><gtr:title>Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19d066d8e399eeefd6d789616fbf1279"><gtr:id>19d066d8e399eeefd6d789616fbf1279</gtr:id><gtr:otherNames>Lewis SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CB5BA97-5CB1-46A4-9380-64E996013D16"><gtr:id>4CB5BA97-5CB1-46A4-9380-64E996013D16</gtr:id><gtr:title>A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cd753fda3bce2547bbdf1a5e6b8c20d2"><gtr:id>cd753fda3bce2547bbdf1a5e6b8c20d2</gtr:id><gtr:otherNames>Lane JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900871</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>